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Glossary {#s9110}
========

AminoacylaseAn enzyme that catalyzes the deacylation of *N*-acetyl-L-amino acids including mercapturates.BioactivationA process by which a compound is converted to a metabolite that is more toxic then the original compound---also known as toxification.Cysteine *S*-conjugate *N*-acetyltransferaseAn enzyme that catalyzes the last step in the mercapturate pathway and that uses acetyl-CoA as the acetyl donor.Cysteine *S*-conjugate β-lyasesPyridoxal 5′-phosphate (PLP)-containing enzymes that catalyze a net reaction in which a cysteine *S*-conjugate is converted to pyruvate, ammonium ion, and a sulfur-containing fragment.DeconjugationRemoval of an intact cysteine-containing moiety (usually as glutathione) from the *S*-conjugate.DipeptidasesEnzymes that convert cysteinylglycine *S*-conjugates to cysteine *S*-conjugates and glycine, including aminopeptidase M, cysteinylglycine dipeptidase, and possibly leucyl aminopeptidase.Glutamine transaminase K (GTK)An enzyme of high specific activity in kidney but present in most organs. The enzyme catalyzes reversible transamination with glutamine, aromatic amino acids, and a large number of sulfur-containing amino acids. It also catalyzes very effective cysteine *S*-conjugate β-lyase reactions. In addition, it is exceptionally active as both an aminotransferase and a β-lyase with many selenocysteine *Se*-conjugates.Glutathione *S*-transferasesA family of enzymes that catalyzes the reaction of the cysteinyl anion of glutathione with an electrophile generating the corresponding glutathione *S*-conjugate.Mercapturate pathwayA pathway that converts endogenous or exogenous electrophiles to their *N*-acetyl cysteine *S*-conjugate (mercapturate). The mercapturates are generally more polar and water soluble than the original electrophiles and are readily excreted in the urine and/or bile.Mitochondrial aspartate aminotransferaseA very important enzyme in amino acid metabolism and present in high amounts in all cells that contain mitochondria. The enzyme is important in linking amino acid metabolism to the TCA cycle (and to the urea cycle in the liver) and in the transfer of reducing equivalents from cytosol to mitochondrion in lieu of NADH. It is also a prominent mitochondrial cysteine *S*-conjugate β-lyase.*S*-ConjugatesThe first conjugate to be formed in the mercapturate pathway is the glutathione *S*-conjugate. The reaction may occur spontaneously between glutathione and electrophile but is most often catalyzed or accelerated by glutathione *S*-transferases. The glutathione *S*-conjugate is then successively converted to cysteinylglycine *S*-conjugate, cysteine *S*-conjugates, and *N*-acetyl cysteine *S*-conjugate.ThioacylationA process whereby a reactive sulfur-containing fragment generated from a cysteine *S*-conjugate β-lyase reaction on a cysteine *S*-conjugate derived from a halogenated alkene reacts with ε-amino groups of key lysine residues in susceptible proteins.Thiomethyl shuntA series of reactions in which sulfur is added to an electrophile via the cysteine *S*-conjugate β-lyase pathway followed by an enzyme-catalyzed *S*-methylation reaction with *S*-adenosyl-[l]{.smallcaps}-methionine as methyl donor. The resulting thiomethyl compound may be excreted unchanged or following oxidation to a sulfoxide/sulfone.Toxicant channelingA hypothesis in which it is suggested that reactive sulfur-containing species generated from toxic cysteine *S*-conjugates are channeled from the active site of mitochondrial aspartate aminotransferase to α-ketoglutarate dehydrogenase complex, thereby accounting for the remarkable sensitivity of this enzyme complex to inactivation in tissues/cells exposed to certain toxic cysteine *S*-conjugates. The process may be of wider applicability if cysteine *S*-conjugate β-lyases (other than aspartate aminotransferase) are present in tight metabolic linkages with other enzymes.γ-Glutamyl leukotrienaseA unique enzyme of the γ-glutamyltransferase family that metabolizes the glutathione *S*-conjugate of leukotriene (LTC~4~), converting LTC~4~ to LTD~4~ (the cysteinylglycine *S*-conjugate of leukotriene).γ-GlutamyltransferaseAn enzyme that catalyzes the removal of the glutamate moiety from glutathione *S*-conjugates, generating the corresponding cysteinylglycine *S*-conjugates. Usually, the acceptor molecule is water so that the other products of the reaction is glutamate. However, at exceptionally high, nonphysiological concentrations, amino acids or dipeptides may be γ-glutamyl acceptors, generating a γ-glutamyl amino acid or a γ-glutamyl dipeptide, respectively. The enzyme is also referred to as γ-glutamyl transpeptidase and GGT1.

10.17.1. Introduction {#s0010}
=====================

Mercapturic acids (*S*-(*N*-acetyl)-[l]{.smallcaps}-cysteine conjugates) were first identified over 135 years ago and were soon recognized to play a role in the detoxification of certain halogenated xenobiotics ([@bib0180]). However, it was not until 1959 that the tripeptide glutathione (γ-glutamylcysteinylglycine, GSH) was recognized as the source of the cysteinyl portion of mercapturates ([@bib0160], [@bib0255]). GSH is found in almost all bacterial, plant, and mammalian cells in high concentration, typically 0.5--12 mmol l^− 1^ ([@bib2075], [@bib2100]). The mercapturate pathway begins with the formation of a thioether bond between GSH and a xenobiotic in a reaction catalyzed (or enhanced) by glutathione *S*-transferases (GSTs). Subsequently, the resulting glutathione *S*-conjugate is converted to a cysteinylglycine *S*-conjugate by γ-glutamyltransferase (GGT) and thence to a cysteine *S*-conjugate by various peptidases. Finally, the cysteine *S*-conjugate is *N*-acetylated to the corresponding *N*-acetyl-[l]{.smallcaps}-cysteine *S*-conjugate (mercapturate). The mercapturate is generally more water soluble than is the parent compound and is more readily excreted. (For reviews, see [@bib0340], [@bib1990], [@bib2075].) Reactions involved in and associated with the mercapturate pathway are shown in [Fig. 1](#f0010){ref-type="fig"} .Fig. 1The mercapturate pathway and associated side reactions. If the mercapturate precursor contains an electrophilic center, it may react directly with GSH (reaction [1](#fo0010){ref-type="disp-formula"}). Alternatively, the precursor may be converted to a compound with an electrophilic center (reaction [2](#fo0015){ref-type="disp-formula"}) prior to reaction with GSH. Reactions [(1)](#fo0010){ref-type="disp-formula"}, [(2)](#fo0015){ref-type="disp-formula"}, [(3)](#fo0020){ref-type="disp-formula"}, [(4)](#fo0025){ref-type="disp-formula"}, [(5)](#fo0030){ref-type="disp-formula"} represent the mercapturate pathway. Reactions [(7)](#fo0040){ref-type="disp-formula"}, [(8)](#fo0045){ref-type="disp-formula"}, [(9)](#fo0050){ref-type="disp-formula"} are alternative reactions for elimination of cysteine *S*-conjugates. Reactions [(7)](#fo0040){ref-type="disp-formula"} plus [(8)](#fo0045){ref-type="disp-formula"} denote the thiomethyl shunt. The thiomethyl compound (XSCH~3~) may be excreted unchanged or further oxidized to sulfoxide, sulfone, or CO~2~ and sulfate, which are excreted. For some cysteine *S*-conjugates, metabolism may also involve conversion to the α-keto acid, α-hydroxy acid, and oxidatively decarboxylated product (see "[Deamination and Transamination](#s0140){ref-type="sec"}" section). The cysteine *S*-conjugate may also be converted to the corresponding sulfoxide. Enzymes involved: (1) glutathione *S*-transferases (GSTs), (2) oxidases that generate an electrophilic center for attack by GSH (in some cases oxidation may be nonenzymatic), (3) ectoenzyme γ-glutamyltransferase (GGT), (4) ectoenzymes APN/cysteinylglycine dipeptidase and possibly cytosolic leucyl aminopeptidase, (5) *N*-acetyltransferases, (6) aminoacylases, (7) cysteine *S*-conjugate β-lyases, (8) thiomethyltransferase, and (9) UDP-glucuronosyltransferases. Many potentially toxic xenobiotics and a few endogenous compounds are metabolized through the mercapturate pathway. *AdoHcy*, *S*-adenosyl-[l]{.smallcaps}-homocysteine and *AdoMet*, *S*-adenosyl-[l]{.smallcaps}-methionine.Modified from Silbernagl, S., Heuner, A., 1993. In Anders, M.W., Dekant, W., Henschler, D., Oberleithner, H., Silbernagl, S. (eds.), Renal Disposition and Nephrotoxicity of Xenobiotics. Academic Press, Inc., San Diego, CA. pp. 135--154. Cooper, A.J.L., Pinto, J.T., 2008. In Elfarra, A.A. (ed.), Biotechnology: Pharmaceutical Aspects. Advances in Bioactivation Research. Springer, New York, NY.

Reactions involved in drug metabolism were originally assigned to two general categories ([@bib2410]). Phase I transformations serve to unmask a functional group and may involve reactions such as oxidation, hydrolysis, and reduction. Phase II transformations generate highly polar derivatives (conjugates), such as glucuronides and sulfate esters, which are excreted into the urine. Almost all these transformations are catalyzed by transferases ([@bib0390]). It was originally thought that phase II reactions complete the processes begun by phase I transformations. Others have suggested that elimination of the glutathione *S*-conjugate from the cell may represent a phase III detoxification event ([@bib1035]). It is now apparent that many xenobiotics are metabolized entirely by pathways that do not involve phase I reactions. Thus, many glutathione *S*-conjugates are formed from drugs and other xenobiotics without prior transformation. Moreover, glutathione *S*-conjugates are rarely excreted by the kidney because of their large size and amphiphilic character and the presence of GGT and dipeptidases in the proximal tubules. Glutathione *S*-conjugates are often excreted into the bile ([@bib0590], [@bib1465], [@bib2000]) and/or further metabolized, especially to the mercapturate. As a result of ambiguities in classification, some authors have suggested that it may be time to discontinue the designations "phase I" and "phase II" metabolism ([@bib1125]).

Notwithstanding how one classifies the transformations of xenobiotics through the mercapturate pathway, it is clear that the mercapturate pathway serves as a biochemical defense against potentially harmful electrophilic xenobiotics. Moreover, in special cases, the pathway may serve also to metabolize endogenously generated substances such as leukotrienes ("[γ-Glutamyl leukotrienase](#s0065){ref-type="sec"}" and "[Deactivation/Detoxification](#s0105){ref-type="sec"}" sections). However, in other cases, a diversion of the pathway leads to the bioactivation of xenobiotics rather than to a detoxification. Thus, cysteine *S*-conjugates formed from some halogenated alkenes are converted to pyruvate, ammonium ion, and a reactive, toxic fragment by the action of cysteine *S*-conjugate β-lyases ("[Background: Bioactivation of Halogenated Alkenes](#s0165){ref-type="sec"}" section). Leukotriene transformations and cysteine *S*-conjugate β-lyases are considered in more detail in the succeeding text.

The purpose of this article is to provide a review of the enzymes involved in the mercapturate pathway and their biological importance in relation to reactions with endogenous and xenobiotic substances. The article also deals at some length with nonenzymatic and enzymatic processes that divert glutathione *S*-conjugate and cysteine *S*-conjugate away from the mercapturate pathway.

Some of the points discussed in this article have been adapted from reviews by [@bib0590], [@bib0100], [@bib0455], and [@bib0500].

10.17.2. Enzymes of the Mercapturate Pathway {#s0015}
============================================

10.17.2.1. Glutathione *S*-Transferases (GSTs) {#s0020}
----------------------------------------------

GSH has many biological roles, including (1) defense against reactive oxygen species and free radicals, (2) defense against reactive electrophiles, though the action of GSTs (3) carrier of cysteine in a less reactive form, (4) cofactor in several enzyme reactions, (5) participation in eicosanoid biology, (6) maintenance of cellular redox state, and (7) transport of cysteine (e.g., [@bib2100]). Recently, it has become apparent that GSTs have important roles, for example, in catalyzing addition of GS^−^ to cyst(e)ine residues resulting in protein glutathionylation ([@bib1520], [@bib2170]) and in the regulation of mitogen-activated protein kinases ([@bib2145]). Many drugs and other xenobiotics or their metabolites are directly electrophilic and are thus capable of causing cellular damage in vivo. By intercepting these potentially harmful electrophiles, GSH is important in the defense against foreign substances. GSH is a "soft" nucleophile (i.e., the sulfur is of low electronegativity and high polarizability and is easily oxidized) and preferentially reacts with "soft" electrophiles (i.e., compounds that contain an acceptor atom with high polarizability, low electronegativity, and often unshared *p* or *d* valence electrons). Thus, reactions of GSH with electrophiles often proceed at a measurable rate in the absence of a catalyst ([@bib1205]), but in general, the reaction is accelerated by the action of GSTs. These enzymes are widespread in nature and are present in most mammalian tissues. In the mammalian liver, GSTs account for \> 3--10% of the soluble protein ([@bib1155]). The cytosolic forms are dimers with monomer *M* ~r~ of ∼ 25 × 10^3^. Many GST isozymes have been identified in the rat ([@bib1155]). Cytosolic GSTs are now usually classified into several classes (A (alpha), M (mu), P (pi), T (theta), Z (zeta), O (omega), and S (sigma)) according to their isoelectric point, substrate and inhibitor properties, antibody recognition, and N-terminal amino acid sequences. GSTs may also be broadly classified on the basis of their cellular location, namely, microsomal, mitochondrial, and cytosolic ([@bib0915]). The enzymes contain a binding site for GSH (nucleophile) and a separate binding site for hydrophobic compounds with electrophilic centers. GSTs are highly specific for GSH as the nucleophile but, depending on the isozyme, exhibit wide and overlapping substrate specificities with regard to the electrophilic substrate. Binding of GSH to the active site facilitates ionization to the nucleophilic thiolate anion (GS^−^) ([@bib1155]).

GSH conjugation can occur by three mechanisms ([@bib0090], [@bib0100]). For example, haloalkenes and dichloroacetylene undergo GST-catalyzed vinylic substitution (S~N~V) reactions that may be either a Michael addition reaction (e.g., with tetrafluoroethylene (F~2~C000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000CF~2~, Eq. [1](#fo0010){ref-type="disp-formula"}) and dichloroacetylene (ClC000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000CCl, Eq. [2](#fo0015){ref-type="disp-formula"})) or an addition--elimination reaction (e.g., with trichloroethylene (Cl(H)CCCl~2~, Eq. [3](#fo0020){ref-type="disp-formula"})). GSTs also catalyze reactions with epoxide moieties (e.g., in the conversion of leukotriene A~4~ (LTA~4~) to leukotriene C~4~ (LTC~4~)). Glutathione *S*-conjugate formation with haloalkenes is catalyzed by both microsomal (MGST1) and cytosolic GSTs in ratios that depend to some extent on the structure of the haloalkene ([@bib0455] and references cited therein).$$\left. F_{2}C = {CF}_{2} + {GS}^{-} + H^{+}\rightarrow F_{2}C\left( H \right){CF}_{2}SG \right.$$ $$\left. ClC\text{≡}CCl + {GS}^{-} + H^{+}\rightarrow ClC\left( H \right) = C\left( {Cl} \right)SG \right.$$ $$\left. Cl\left( H \right)C = {CCl}_{2} + \ {GS}^{-}\rightarrow ClC\left( H \right) = C\left( {Cl} \right)SG\  + \ {Cl}^{-} \right.$$

Interestingly, despite their generally broad specificity, many mammalian GSTs are able to catalyze stereoselective addition of GSH to some electrophiles ([@bib0155], [@bib0605], [@bib1400], [@bib1445], [@bib1855]). Some bacterial GSTs also exhibit stereoselectivity ([@bib0730]).

10.17.2.2. γ-Glutamyltransferases {#s0025}
---------------------------------

### 10.17.2.2.1. GGT family of enzymes {#s0030}

In 1959, it was postulated that a glutathionase (an enzyme that degrades GSH) plays a role in the formation of mercapturic acids ([@bib0255]). Previously, [@bib0205] had demonstrated that the first step in the metabolism of GSH is cleavage of the γ-glutamyl bond followed by cleavage of the cysteinylglycine peptide bond. The enzyme that cleaves the γ-glutamyl bond of GSH and glutathione *S*-conjugates was subsequently isolated and named γ-glutamyltransferase (GGT, also known as γ-glutamyltranspeptidase; [@bib1705], [@bib2090]). A second enzyme that cleaves γ-glutamyl bonds (converting the glutathione *S*-conjugate LTC~4~ to the corresponding cysteinyl-glycine conjugate LTD~4~) was identified independently by two groups in the 1990s and named GGT-rel and γ-glutamyl leukotrienase ([@bib0315], [@bib0925]).

In humans, the genes that encode GGT and γ-glutamyl leukotrienase are located in close proximity on the long arm of chromosome 22, in an area of the genome that has undergone multiple duplications ([@bib0135], [@bib0280], [@bib0925]). With the cloning of the human genome, *GGT* pseudogenes and genes encoding truncated portions of GGT have been identified, in addition to several genes that theoretically could encode a full-length protein ([@bib0930]). Recent studies of a gene named *GGT2*, which is present only in humans and has 97% nucleotide identity and 94% amino acid identity with human *GGT*, have shown that this gene does not encode a functional protein ([@bib2380]). GGT2 mRNA is expressed, and the protein is synthesized, but the protein does not autocleave into an active enzyme and is rapidly degraded ([@bib2380]). To date, only GGT and γ-glutamyl leukotrienase have been shown to be expressed as functional proteins.

Heisterkamp and colleagues have collaborated with the Human Genome Organization (HUGO) Gene Nomenclature Committee to standardize the nomenclature for the GGT gene family ([@bib0930]). This nomenclature designates γ-glutamyltransferase as GGT1 and γ-glutamyl leukotrienase as GGT5. For clarity, throughout this article, we will continue to use the descriptive names γ-glutamyltransferase (GGT) and γ-glutamyl leukotrienase. Homologues of GGT are expressed throughout the plant and animal kingdoms ([@bib1490], [@bib1595], [@bib2195], [@bib1355], [@bib1865], [@bib2295]).

### 10.17.2.2.2. Protein structure {#s0035}

GGT is a type II membrane protein with a single transmembrane domain within the large subunit ([@bib0400], [@bib0780], [@bib1800], [@bib1890]). Human GGT consists of 569 amino acids ([@bib0780], [@bib1800], [@bib1890]). Only the first four amino acids of the N-terminus extend into the cytosol (see [Fig. 2](#f0015){ref-type="fig"} ). All of the enzymatic activity takes place in the extracellular portion of the enzyme ([@bib0970], [@bib2175]). The enzyme is translated as a single polypeptide chain and autocleaves into two subunits that remain noncovalently bound to each other ([@bib1170], [@bib1635], [@bib2365]). Both subunits are required for activity ([@bib0735]). The human enzyme contains seven potential *N*-glycan sites. *N*-Linked glycans have been isolated from GGT and characterized ([@bib2440], [@bib2445], [@bib2450], [@bib2370]).Fig. 2Diagrammatic structure of γ-glutamyltransferase (GGT). The enzyme is composed of two noncovalently attached subunits. The larger subunit traverses the cellular membrane such that most of the protein is exposed to the extracellular milieu. The smaller subunit is entirely within the extracellular milieu. As a result of its location, GGT is often referred to as an ectoenzyme. GGT catalyzes the hydrolysis of the γ-glutamyl compound to free glutamate and R. At high pH and in the presence of millimolar concentrations of some dipeptides, amino acids, or GSH (as acceptor molecules), the enzyme can catalyze a transpeptidation reaction to generate a γ-glutamyl acceptor and R. Under physiological conditions, however, the GGT reaction is a hydrolysis reaction.

A detailed study of the *N*-glycosylation of GGT from the human liver and kidney showed tissue-specific and site-specific *N*-glycosylation of GGT in normal human tissues ([@bib2370]). Rat GGT has been shown to contain two *O*-linked glycans, but no *O*-linked glycans have been reported for human GGT ([@bib0230]). Cotranslational *N*-glycosylation is required for proper folding and autocleavage of the human GGT propeptide into two subunits, although the *N*-glycans can be removed from the mature enzyme without altering its stability or catalytic activity ([@bib2375]). In addition, a CX3C motif within GGT is also required for proper folding and autocleavage ([@bib2380]). Treatment of the large subunit by papain or bromelain releases a hydrophilic form of the enzyme that is catalytically indistinguishable from the intact membrane-bound enzyme ([@bib0990], [@bib0995]). The crystal structure of human GGT has recently been solved ([@bib2385]). The crystal structures of GGT homologues from *Escherichia coli*, *Helicobacter pylori*, and *Bacillus subtilis* were reported previously ([@bib1595], [@bib1680], [@bib2320]), but the structure of the human enzyme is the first report for any eukaryotic GGT. The crystal structure of the human enzyme reveals a substrate channel with Thr-381, the catalytic nucleophile, in the deepest part of the cleft ([@bib2385]). Many other insights into the enzyme were gained from an analysis of the structure, including the presence of a bimodal switch in the orientation of the catalytic nucleophile and the open conformation of the lid loop region of the enzyme ([@bib2385]).

### 10.17.2.2.3. Expression of GGT {#s0040}

In the rat, *GGT* is a single copy gene, and its expression is regulated by five tandemly arranged promoters that give rise to seven different transcripts, all of which encode the same protein but have distinct 5′-untranslated regions (UTRs) ([@bib0370]). The promoters are tissue-specific, and AP-1, AP-2, and nuclear factor κB (NFκB) binding sites have been identified in the promoter region ([@bib0370]). In the mouse, *GGT* is a single copy gene that can be transcribed from seven different promoters, which give rise to distinct mRNAs that encode the same protein but differ in their 5′-UTR ([@bib1380]). Induction of GGT is tissue-specific, and murine GGT mRNA has been shown to undergo tissue-specific and developmentally regulated alternative splicing, which gives rise to both active and enzymatically inactive GGT proteins ([@bib0370], [@bib1130]). Binding sites for AP-1 and the redox-sensitive transcription factors AP-2 and NFκB have been identified in the murine promoters ([@bib0370]). Expression of *K*-*ras* and *Myc* oncogenes has been shown to increase the transcription of *Nrf2* and induce a series of genes including *GGT*, all of which are important in the cellular response to ROS ([@bib0595]). In Nrf2-deficient cells, GGT mRNA is reduced and is not altered by expression of the oncogenic *K*-*ras*, indicating that K-ras is signaling through Nrf2 to induce GGT mRNA. This was confirmed in *Nrf2* knockdown studies.

The transcriptional regulation of *GGT* in humans is tissue-specific with multiple mRNAs encoding the same open reading frame but differing in their 5′-UTR ([@bib2300], [@bib0555]). The human *GGT* promoter contains binding sites for AP-1, AP-2, CREB, GRE, and NFκB and two binding sites for Sp1 ([@bib2300], [@bib1820]). The 5′-UTR of human *GGT* also contains multiple steroid modulatory elements ([@bib0600]). Tumor necrosis factor alpha (TNFα) was shown to induce GGT expression through the NFκB signaling pathway in the human chronic myelogenous leukemia cell lines K562 and MEG-01 ([@bib1820]).

Five distinct mRNAs that encode GGT have been identified in humans and six in mice, and multiple mRNAs have also been identified in rats and pigs ([@bib0370], [@bib0555], [@bib2300]). In each species, the mRNAs all encode the same protein but differ in their UTR. The sequence of the UTR reveals use of multiple promoters that are regulated in a tissue-specific manner. In vertebrates, GGT is constitutively expressed at a high level on the apical surface of the renal proximal tubules, the site of formation of mercapturates from glutathione *S*-conjugates in the kidney ([@bib0845], [@bib1355], [@bib2440], [@bib2445]). In some tissues, GGT can be induced. The promoters contain binding sites for Nrf2, Ap-1, Ap-2, and NFκB transcription factors, and induction of GGT under conditions of redox stress has been demonstrated in several species ([@bib1820], [@bib1130], [@bib0595], [@bib0835]). In the mouse, alternative splicing of the mRNA has been shown to produce at least three GGT isoforms ([@bib0370], [@bib0595]). One of the splicing events is developmentally regulated ([@bib1130]). In humans, the high level of nucleotide sequence homology between human *GGT* and *GGT2* has resulted in a lack of specificity among some of the primers designed for *GGT*, which is a confounding variable in many microarray studies of GGT expression in human tissues ([@bib2380]).

### 10.17.2.2.4. Localization of GGT {#s0045}

GGT is expressed on the apical surface of glands and ducts of many tissues within the human body ([@bib0845]). The highest level of GGT expression is on the surface of the renal proximal tubules. Secretory and absorptive epithelial cells in glands in the testes, endocervix, endometrium, adrenals, prostate, intestinal crypts, sweat glands, and salivary glands all express GGT. In the liver, GGT is localized to the bile canaliculi of hepatocytes and bile ducts. GGT is also expressed on the apical surface of pancreatic acinar cells, and activity can be detected in pancreatic juice and bile ([@bib1260]). Capillary endothelium in the brain and spinal cord also expresses GGT. GSH and glutathione *S*-conjugates present in fluids that flow through these ducts are metabolized by GGT.

### 10.17.2.2.5. Reactions catalyzed by GGT {#s0050}

GGT catalyzes the cleavage of γ-glutamyl bonds ([Fig. 2](#f0015){ref-type="fig"}). A large number of γ-glutamyl compounds in which the glutamate moiety is unrestricted except for the γ-glutamyl bond are substrates for GGT. These include GSH, GSSG, glutathione *S*-conjugates, γ-glutamyl amino acids, and γ-glutamyl *p*-nitroanilide (a substrate commonly used to assay enzyme activity) ([@bib1700], [@bib1710], [@bib2395]). The γ-glutamyl group of the substrate is transiently bound to the enzyme, and the reaction proceeds through a modified ping-pong mechanism ([@bib1145]). The crystal structure of the human enzyme cocrystallized with glutamate showed that the α-carboxylate of the γ-glutamyl moiety of the substrate is stabilized within the active site of the enzyme by forming hydrogen bonds with Arg-107, Ser 451, and Ser-452S ([@bib2385]). The α-amino group forms a salt bridge with Glu-420. Cleavage of the γ-glutamyl bond of the substrate, the first step in the reaction, results in the formation of an acyl bond between the glutamate and the catalytic threonine of the enzyme with the release of all but the glutamate portion of the substrate. The glutamate is released from the enzyme when the enzyme/γ-glutamyl complex reacts either with a water molecule, yielding glutamate and free enzyme, or with the α-amine of an acceptor molecule (transferase or transpeptidase reaction), yielding a γ-glutamyl amino acid and free enzyme ([@bib2095]). The α-amine of a free amino acid or a dipeptide can serve as an acceptor for the γ-glutamyl group ([@bib2150]). The enzyme is routinely assayed by the development of a yellow color upon the release of *p*-nitroaniline from γ-glutamyl-*p*-nitroanilide. The addition of an acceptor such as glycylglycine in a large excess (10- to 40-fold excess relative to the substrate concentration) accelerates the rate of the reaction ([@bib2150]). The standard biochemical assay is conducted at pH 8.5, the pH optimum of the transferase reaction.

Analysis of the kinetics of the reaction indicated that, in the kidney, the GGT reaction is a hydrolysis reaction under physiological conditions due to the reduced pH in the proximal tubule and the rapid removal of amino acids ([@bib0540]). The essential nature of this reaction was established with the development of GGT knockout strains of mouse ([@bib1385]). GGT-null mice were born at expected ratios with no apparent phenotypic abnormalities. However, they excreted high levels of GSH in their urine, failed to grow at the same rate as their wild-type littermates, and died by 10 weeks of age from a cysteine deficiency. GGT-null mice can be rescued by supplementing them with *N*-acetyl cysteine. Earlier work with cultured cell lines had shown that expression of GGT enables cells to initiate the release of cysteine from extracellular GSH ([@bib0855]). GSH cannot be taken up intact by most cells. In the knockout mice, GSH present in the glomerular filtrate passes intact through the proximal tubules and is excreted into the urine ([@bib1385]). In wild-type mice, GGT localized to the apical surface of the proximal tubules cleaves the γ-glutamyl bond releasing glutamate and cysteinylglycine. The cysteinylglycine dipeptide can be cleaved into cysteine and glycine by any of several dipeptidases present on the apical surface of the proximal tubule cells ("[Hydrolysis of Cysteinylglycine and Its Conjugates](#s0070){ref-type="sec"}" section). Cysteine can be synthesized from methionine or through a salvage pathway, but the knockout mice are not able to maintain an adequate supply of cysteine for growth and development while continuously excreting large amounts of GSH in the urine. The GGT knockout mouse becomes deficient only in cysteine, indicating that uptake of amino acids does not depend on GGT, as had been proposed by some investigators ([@bib1710]). A physiological role for the transferase reaction has not been demonstrated. A novel assay that measures the GGT hydrolysis reaction at physiological pH and osmolarity has shown that the second order rate kinetics for GSH and glutathione *S*-conjugates are similar ([@bib2395]).

### 10.17.2.2.6. Inhibitors of GGT {#s0055}

Glutamine analogs including acivicin, 6-diazo-5-oxo-**[l]{.smallcaps}**-norleucine, and **[l]{.smallcaps}**-azaserine inhibit GGT ([@bib2115]). However, these glutamine analogs are neurotoxic and cannot be used clinically ([@bib0050], [@bib0940]). γ-Phosphono diester analogs of glutamate have also been shown to be potent inhibitors of GGT ([@bib0830], [@bib1630]). *S*-Alkyl **[l]{.smallcaps}**-homocysteine analogs function as competitive inhibitors ([@bib1415]). Finally, a new class of uncompetitive inhibitors of GGT has also been reported ([@bib1165], [@bib2400], [@bib2405]). Structures of bacterial GGT and human GGT with inhibitors bound provide insight into the mechanism of inhibition of the enzyme ([@bib0985], [@bib2140], [@bib2315], [@bib2320]).

### 10.17.2.2.7. GGT and disease {#s0060}

The half-life of GGT in rat renal tissue is 35 h ([@bib0305]). The enzyme is induced by oxidative stress ([@bib1725], [@bib0370], [@bib1820], [@bib0595]). GGT is expressed in many tumors and contributes to resistance to chemotherapy ([@bib0865], [@bib0870], [@bib1785]). GGT is upregulated in preneoplastic foci of hepatocytes in rats treated with toxic hepatocarcinogens ([@bib0850]). Elevated levels of enzymatically active GGT can be detected in the serum of patients with liver and pancreatic disease, including inflammatory disease and cancer ([@bib0665], [@bib2390], [@bib1360]). Studies in animal models indicate that inhibitors of GGT may be useful in the treatment of asthma and reperfusion injury ([@bib2435], [@bib2190]). GGT activity is also detectable in some commercial lots of bovine serum that are used to maintain cells in culture and can affect studies involving GSH synthesis and regulation ([@bib0860]).

### 10.17.2.2.8. γ-Glutamyl leukotrienase {#s0065}

As noted earlier, [@bib0925] identified a GGT-related gene, *GGT*-*rel*, in a human cDNA library. The product of this gene (i.e., GGT-rel) was shown to cleave the γ-glutamyl bond of LTC~4~ (a glutathione *S*-conjugate) but not the γ-glutamyl substrates routinely used to assay GGT activity. The nucleotide sequence revealed 39.5% identity between the amino acid sequences of GGT and GGT-rel. The similarity included a hydrophobic domain (amino acids 12--28) similar in location to the transmembrane domain of GGT, indicating that GGT-rel is also a type II membrane protein with the active site on the cell surface. Analysis of the kinetic activity of human GGT-rel demonstrated that it hydrolyzes the γ-glutamyl bond of glutathione and glutathione conjugates ([@bib2395]). The *K* ~m~ of GGT-rel for the substrates, including GSH, GSSG, and LTC~4~, is similar to those exhibited by GGT, but the rate of the GGT-rel reaction is 37-fold slower than that exhibited by GGT, resulting in a second order rate kinetic for human GGT-rel that is 37-fold lower than for GGT ([@bib2395]). A study of LTC~4~ metabolism in three patients deficient in GGT showed increased levels of LTC~4~ but no detectible level of its metabolite LTD~4~ ([@bib1495]). These data indicate that in humans, LTC~4~ is metabolized primarily by GGT not GGT-rel. Localization of GGT-rel expression in normal human tissues showed it to be expressed by macrophages present in many tissues and cells within the adrenal gland, salivary gland, pituitary, thymus, spleen, liver, bone marrow, small intestine, stomach, testis, prostate, and placenta ([@bib0875]). However, within tissues that express both GGT and GGT-rel, the enzymes are expressed by different cell types and have access to different substrates. GGT-rel is expressed on cell surfaces that are in contact with blood and intercellular fluids, while GGT1 is expressed on cell surfaces that have access primarily to fluids in ducts and glands throughout the body.

The ability of the GGT-null mouse to cleave the γ-glutamyl bond of LTC~4~ and release LTD~4~ led Carter and coworkers to initiate a search for another enzyme that could cleave γ-glutamyl bonds. They identified an enzyme in the mouse they called γ-glutamyl leukotrienase, which has since been shown to be the mouse homologue of GGT-rel ([@bib0315]). Comparison of kidney homogenates from wild-type and GGT-null mice demonstrated that both GGT and GGT-rel cleave LTC~4~ to LTD~4~ ([@bib0310], [@bib0820]). No detailed kinetic studies comparing the activity and substrate specific of mouse GGT and GGT-rel have been published. It has been shown that in the mouse, acivicin inhibits both GGT-rel and GGT, but glycylglycine does not accelerate the velocity of the GGT-rel-catalyzed reaction as is observed for the GGT-catalyzed reaction ([@bib0310], [@bib0315]). In mice, GGT-rel is expressed primarily in the spleen ([@bib0310]). It is observed on endothelial cells and is also localized to the capillaries and sinusoid throughout the body ([@bib0310]). There is also a GGT-rel homologue in the rat ([@bib1795]), although there are no published studies regarding its localization or kinetics.

10.17.2.3. Hydrolysis of Cysteinylglycine and Its Conjugates {#s0070}
------------------------------------------------------------

At least four peptidases/dipeptidases have been identified to cleave cysteinylglycine and its conjugates, including membrane-bound (aminopeptidase N and cysteinylglycine dipeptidase) and cytosolic (a nonspecific enzyme and leucyl aminopeptidase/prolyl aminopeptidase) enzymes ([@bib1790] and references cited therein). Aminopeptidase N (APN), cysteinylglycine dipeptidase, and leucyl dipeptidase are discussed in the succeeding text.

### 10.17.2.3.1. Aminopeptidase N (APN) {#s0075}

The sequence of human APN (synonyms, aminopeptidase M, peptidase E, peptidase I, alanine dipeptidase, and alanyl aminopeptidase) was deduced from the corresponding cDNA ([@bib1690]). The cDNA encodes 967 amino acids per subunit, and the sequence contains 11 possible glycosylation sites. Over the last 25 years, many related enzymes have been sequenced. APN is a type II metalloproteinase that belongs to the M1 family ([@bib1425]). The M1 family consists of at least nine members, five of which are integral membrane proteins ([@bib0075]). They all possess the highly conserved HEXXH(X)18E zinc-binding and GAMEN motifs essential for enzyme activities ([@bib1430]). APN is important in modulating the activity of several peptide hormones ([@bib0075], [@bib1425]). The enzyme also serves as a receptor for coronaviruses and other human viruses and influences immune function, cell proliferation, secretion, and angiogenesis ([@bib1425]).

APN, like GGT, is found in microvillus membranes in many tissues but especially in the renal proximal tubules, small intestine, and epididymis ([@bib1240], [@bib2105], [@bib2110]). APN is a homodimer (*M* ~r~ of the subunit, 130 × 10^3^) that contains two zinc ions per enzyme dimer. The enzyme has a broad specificity toward dipeptides and oligopeptides, amides, and acrylamides. Usually, the N-terminal amino acid is cleaved. The best substrates generally contain an alanine residue at the N-terminus, but almost any amino acid can substitute, including proline. When the N-terminus is a proline followed by a hydrophobic residue, a dipeptide may be cleaved from the N-terminus ([@bib2105], [@bib2110]). As a result, the enzyme can degrade a large number of peptides down to single amino acids (or occasionally dipeptides). The enzyme hydrolyzes a number of endogenous peptides, including the thrombin receptor activation peptide ([@bib0395]). The human enzyme is identical to myeloid marker protein CD 13 ([@bib1420]).

APN is anchored to the apical membranes of the kidney proximal tubules by a hydrophobic stretch of amino acids at the N-terminus. The enzyme, as is the case with GGT, can be readily released from membranes by treatment with papain. The amino acid sequence indicates that this enzyme, like GGT, is synthesized with an uncleaved signal sequence at its N-terminus, which serves as a membrane anchor ([@bib2110]). The human enzyme has been shown to possess an additional sorting signal that allows the enzyme to be segregated in the *trans*-Golgi network and then to the apical membrane ([@bib2360]). APN, like GGT, is glycosylated ([@bib1625], [@bib2110]). An intimate relationship exists between high-mannose glycosylation and polypeptide folding during the synthesis of the mature enzyme, the timing of which is essential for correct polypeptide folding ([@bib0550]).

### 10.17.2.3.2. Cysteinylglycine dipeptidase {#s0080}

Cysteinylglycine dipeptidase (synonyms, dipeptidase 1, cysteinylglycinase, microsomal dipeptidase, renal dipeptidase, and dehydropeptidase 1) is present in the microvilli of epithelial cells. The enzyme is a dimer (*M* ~r~ of the monomer ∼ 50 × 10^3^) and contains four zinc ions per enzyme dimer ([@bib1240], [@bib2105], [@bib2110], [@bib0290], [@bib0295]). The rat enzyme is glycosylated, but the human kidney enzyme apparently is not ([@bib0290]). The enzyme is selectively inhibited by cilastatin, whereas APN is selectively inhibited by bestatin. This selectivity has allowed Tate and coworkers to estimate that about 65%, 60%, and 95% of *S*-methyl-cysteinylglycine-hydrolyzing activities of the rat renal, jejunal, and epididymal membranes are due to cysteinylglycine dipeptidase (reviewed in [@bib2110]). Furthermore, cysteinylglycine dipeptidase is the major activity responsible for the hydrolysis of cysteinyl-bis(glycine) and LTD~4~ in these membranes ([@bib0295], [@bib1240], [@bib2110]). The enzyme is also thought to be responsible for the hydrolysis of some β-lactam antibiotics such as perem and carbaperem ([@bib0290]). The primary structure of the human cysteinylglycine dipeptidase has been deduced from the cDNA by [@bib0020]. The enzyme is located on the surface of the brush-border membranes ([@bib2110]). The cDNA codes for 411 amino acid residues beginning with a signal peptide of 16 residues ([@bib0020]). A highly hydrophobic region of 16 amino acids was deduced to reside at the C-terminus, but the sequence was later shown to be absent from the mature protein expressed in COS cells ([@bib0020]). The enzyme, unlike APN, is refractory to release from membranes with papain ([@bib2110]). It is released, however, by phosphatidylinositol-specific phospholipase C (PI-PLC) ([@bib2110]). The enzyme is converted from an amphipathic to a hydrophilic form by this treatment. [@bib0025] showed that the enzyme is anchored to the membranes at a serine residue via glycosyl phosphatidylinositol. Cysteinylglycine dipeptidase is more active with dipeptides such as cysteinylglycine, [l]{.smallcaps}-cysteinyl-bis(glycine), and *S*-methyl-[l]{.smallcaps}-cysteinylglycine than is APN ([@bib1240]).

### 10.17.2.3.3. Leucyl aminopeptidase {#s0085}

It was originally thought that APN and especially cysteinylglycine dipeptidase are the most important enzymes involved in the hydrolysis of cysteinylglycine and cysteinylglycine *S*-conjugates. However, [@bib1115] have reported that a cytosolic liver cysteinylglycinase catalyzes the hydrolysis of cysteinylglycine and model cysteinylglycine *S*-conjugates. Mammalian cells contain plasma membrane transporters for dipeptides and tripeptides (e.g., [@bib1870]). Thus, formation of the cysteine *S*-conjugate may occur intracellularly and extracellularly. The cytosolic activity may be especially important in species such as guinea pig and human that exhibit high hepatic GGT activity ([@bib1115]). The same group later identified the enzyme as manganese-dependent leucyl aminopeptidase (synonyms, cytosolic aminopeptidase, leucine aminopeptidase, leucine aminopeptidase 3, proline aminopeptidase, and peptidase S; LAP3, LAPEP, and PEPS) ([@bib1120]). These authors provided evidence that leucyl aminopeptidase is the major cysteinylglycine-hydrolyzing activity in the rat liver; leukotriene D4 is, however, a poor substrate ([@bib1120]). This enzyme also appears to be important in GSH turnover in bovine lens ([@bib0300]).

10.17.2.4. Cysteine *S*-Conjugate *N*-Acetyltransferases {#s0090}
--------------------------------------------------------

The last step of the mercapturate pathway is catalyzed by *N*-acetyltransferases. A number of mostly cytosolic *N*-acetyltransferases are known and have been well characterized. Acetyltransferase activity toward alkyl cysteine *S*-conjugates was detected in rat liver slices by [@bib0170]. Subsequently, an acetyltransferase that *N*-acetylates cysteine *S*-conjugates (Eq. [4](#fo0025){ref-type="disp-formula"}) was shown to be present in liver and kidney microsomes ([@bib0790]). Evidence has been presented that the activity in microsomes is due to a single enzyme ([@bib0215]). The enzyme exhibits some activity toward cysteine and methionine but is much more active with *S*-benzyl-[l]{.smallcaps}-cysteine and other cysteine *S*-conjugates. It has no activity with glutamate or aspartate.$$\left. {Acetyl}\text{-}CoA\  + S\text{-}{benzyl}\text{-}L\text{-}{cysteine}\rightarrow CoA\  + N\text{-}{acetyl}\text{-}S\text{-}{benzyl}\text{-}L\text{-}{cysteine} \right.$$

Cysteine *S*-conjugate *N*-acetyltransferase-specific activity is highest in the kidney ([@bib0625], [@bib0630]). Within the kidney, activity is highest in the straight portion of the proximal tubule ([@bib0935]). The enzyme is located on the cytosolic surface of the endoplasmic reticulum ([@bib1685]). The enzyme is difficult to remove from microsomes, but it has been successfully isolated and partially purified from the pig kidney ([@bib0060], [@bib1255]). The purified enzyme was shown to be active with seven nephrotoxic cysteine *S*-conjugates derived from halogenated alkenes ([@bib1255]). The *K* ~m~ values were remarkably similar (∼ 0.1--0.3 mM), but *V* ~max~ values were more varied.

The gene coding for the predominant cysteine *S*-conjugate *N*-acetyltransferase in the kidney and liver is NAT8 (*N*-acyltransferase 8) ([@bib2290]). Interestingly, [@bib2290] found that NAT8 homologues are present in all vertebrate genomes sequenced to the time of publication, where they are often encoded by multiple, tandemly repeated genes that encode xenobiotic metabolizing enzymes.

10.17.3. Interorgan Transport of Mercapturates and Mercapturate Intermediates {#s0095}
=============================================================================

Formation of glutathione *S*-conjugates in the body generally occurs mostly in the liver ([@bib0585], [@bib0590]). Cysteine *S*-conjugates and mercapturates that are formed in the liver are excreted by the kidneys, and therefore, their metabolism involves interorgan transport. The following general discussion applies mainly to the rat. However, other mammals, such as guinea pigs and humans, have much higher levels of hepatic GGT ([@bib0945], [@bib0950], [@bib0955], [@bib0960]), and therefore, metabolic pathways and trafficking of mercapturate intermediates may vary from species to species. We begin with an overview of interorgan transport followed by a discussion of specific glutathione *S*-conjugate transport proteins.

Although some transport of glutathione *S*-conjugates may occur across the sinusoidal membranes (e.g., [@bib1010], [@bib1015]), the major route for the removal of these compounds in the rat liver is via canicular transporters into the bile (e.g., [@bib0065], [@bib0960], [@bib1150], [@bib2310]). The importance of the biliary excretion system is underscored by experiments in which 1-naphthylisothiocyanate (ANIT) was administered to experimental animals. ANIT is a hepatotoxicant that induces portal edema, parenchymal necrosis, and inflammation of the bile duct epithelium. ANIT reacts reversibly with GSH. The conjugate is released to the bile where the reverse reaction results in bile duct damage and increased GSH concentration ([@bib1085]). Biliary cannulation protects rats from the nephrotoxic effects of hexachloro-1,3-butadiene and *p*-aminophenol ([@bib0740], [@bib1640]). This finding also emphasizes the importance of the biliary excretion as a first step in complex multiorgan pathways involved in glutathione *S*-conjugate and cysteine *S*-conjugate metabolism ([@bib0590]).

A number of compounds in addition to ANIT, including isothiocyanates and isocyanates (e.g., methyl isocyanate), can react reversibly with GSH and thereby be disposed throughout the body ([@bib0140]). This ability of the glutathione *S*-conjugate to act as a dispersant of methyl isocyanate, which is widely used in the chemical industry, is worrisome because of the risk to workers of accidental exposure (which was tragically observed in an industrial accident in Bhopal, India, that resulted in a exposure of a large number of people to methyl isocyanate and many deaths ([@bib1895], [@bib1540])). Methyl isocyanate has been shown to target mitochondria and induce chromosomal damage in human kidney epithelial cells in culture ([@bib1535]).

After secretion into the bile, glutathione *S*-conjugates may arrive intact at the small intestine, or they may be sequentially degraded to the corresponding γ-glutamylcysteine and cysteine *S*-conjugates by the action of GGT and dipeptidases, respectively ([@bib1280]). In this context, it is notable that although the specific activity of GGT in the whole adult rat liver is relatively low, the specific activity locally in the luminal membranes of the bile duct epithelium and bile canalicular membranes of hepatocytes is much higher ([@bib2120]).

The mixture of *S*-conjugates in the gut may have at least four fates: (1) excretion with the feces, (2) absorption from the gut to the general circulation and eventual processing in the kidney, (3) recirculation through the enterohepatic system, and (4) metabolism within the gut lumen ([@bib0585], [@bib0590]). Catabolic reactions within the gut lumen may include conversion of cysteine *S*-conjugates to pyruvate, ammonium ion, and a thiol-containing fragment by bacterial cysteine *S*-conjugate β-lyases. The thiol metabolite may be converted to the thiomethyl derivative by thiol *S*-methyltransferase. The thiomethyl compound may be excreted or enter the circulation where it may be further oxidized to a sulfoxide and to a sulfone ([@bib1275]). These reactions are considered in more detail in "[Sulfur Oxidation of Components of the Mercapturate Pathway](#s0145){ref-type="sec"}" and "[Thiomethyl Shunt](#s0150){ref-type="sec"} sections." Some cysteine *S*-conjugates formed in the bile may reenter liver cells to be converted therein to the corresponding mercapturate.

Glutathione *S*-conjugate and cysteine *S*-conjugate are taken up by the gut, but the uptake of cysteine *S*-conjugates is generally more efficient ([@bib0770]). The presence of GGT and dipeptidase(s) in the microvilli of the brush border of the enterocytes ([@bib2120]) ensures that at least some of the glutathione *S*-conjugates are metabolized within the enterocyte, resulting in release of the cysteine *S*-conjugate to the circulation. In some cases, the mercapturate may be formed in the small intestinal cells and released to the circulation ([@bib0785]). However, in other cases, some glutathione *S*-conjugates may enter the circulation from the brush-border membranes of the gut cells via a mechanism that does not require GGT. This transporter may be identical to the GSH transporter ([@bib0590]).

GSTs are widespread among different tissues. Therefore, it is possible that although glutathione *S*-conjugates are usually made preferentially in the liver, some may be made elsewhere in the body. Indeed, for several xenobiotics, a major site for cysteine *S*-conjugate formation appears to be the kidney ([@bib0890], [@bib1140], [@bib1200]). The glutathione *S*-conjugates released to the circulation from the liver, gut, and other organs or generated directly in the kidney may be further processed in the kidney. Studies with isolated perfused rat kidneys revealed efficient renal removal of the glutathione *S*-conjugate and cysteine *S*-conjugate of hexachlorobutadiene ([@bib1940], [@bib1945]). Removal of the conjugates by the kidneys was associated with toxicity. The nephrotoxicity was blocked by the GGT inhibitor AT-125 (([l]{.smallcaps}-αS,5S)-α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid) and by aminooxyacetate (AOA), indicating the involvement of GGT and a cysteine *S*-conjugate β-lyase, respectively, in the nephrotoxicity of hexachlorobutadiene *S*-conjugates ([@bib1940]; see "[Role of the Mercapturate Pathway and Cysteine S-Conjugate β-Lyases in the Bioactivation of Toxic Halogenated Alkenes](#s0220){ref-type="sec"}" section).

Glutathione *S*-conjugates transported in the blood are generally too small to be retained by the glomerulus and enter the proximal tubules as part of the glomerular filtrate. Glutathione *S*-conjugates produced by the renal tubule cells can also be excreted into the lumen of the tubule ([@bib1245]). The glutathione *S*-conjugate is metabolized at the brush-border membranes by GGT and APN/dipeptidase ([@bib0980], [@bib1100]). In this process, the glutamate is released to generate a cysteine *S*-conjugate and glycine ([@bib0540]). The cysteine *S*-conjugates produced in the tubules (and *S*-conjugates arising from tissues other than the kidney reaching the tubular lumen via glomerular filtration) may be transported into the renal epithelial cells from the glomerular filtrate by active and passive uptake mechanisms ([@bib0090]). Both Na^+^-dependent and Na^+^-independent transporters have been implicated in the renal uptake of *S*-(1,2-dichlorovinyl)-[l]{.smallcaps}-cysteine (DCVC, the cysteine *S*-conjugate of trichloroethylene) (e.g., [@bib0090], [@bib1305], [@bib1910], [@bib1915]). Most of these studies have focused on uptake of DCVC across the basolateral (peritubular) membrane of the renal proximal cells. [@bib2415] showed that DCVC is taken up by a Na^+^-dependent transport system in isolated renal brush-border membrane vesicles. Several neutral amino acids but especially phenylalanine, cysteine, and leucine compete with uptake of DCVC across the luminal membrane in this system ([@bib2415]).

The probenecid-sensitive organic ion transporter on the basolateral side of the proximal tubular cells appears to play the most important role in the accumulation of *S*-conjugates and in the renal toxicity of certain halogenated conjugates ([@bib0590], [@bib1780]). The transporter has high affinity for haloalkene-derived mercapturates but is also active with glutathione *S*-conjugates and cysteine *S*-conjugates with lipophilic attachments to the sulfur ([@bib1305], [@bib2215]). Probenecid protects against the nephrotoxicity of certain haloalkene-derived *S*-conjugates in vivo, probably by blocking the uptake of the mercapturate ([@bib2470]). Indeed, probenecid protects isolated kidney cells from toxic mercapturates derived from haloalkenes and hydroquinones ([@bib1210]).

Once within the renal cells, the cysteine *S*-conjugates may have three fates ([@bib0590]). They may be secreted unchanged for further metabolism, principally within the liver. [@bib2205] have described the presence of two energy-dependent uptake systems for leukotriene E~4~ in rat hepatocytes that are not inhibited by GSH or GSSG. Cysteine *S*-conjugates taken up within the liver are thought to be converted to the corresponding mercapturates and secreted to the plasma to be eventually excreted in the urine ([@bib1000], [@bib1005], [@bib1020]). The cysteine *S*-conjugates within the kidney may also be *N*-acetylated to the corresponding mercapturate and excreted in the urine ([@bib0935]) or be converted by cysteine *S*-conjugate β-lyases to pyruvate, ammonium ion, and a fragment consisting of the original electrophile modified to contain an ---SH group ("[The Cysteine S-Conjugate β-Lyase Reaction](#s0175){ref-type="sec"}" section). As indicated in the foregoing discussion, once formed in the kidney or transported to the kidney, mercapturates are excreted in the urine. Mercapturates may also be released from the kidneys to the general circulation. However, mercapturates are also capable of being cleaved to cysteine *S*-conjugates by acylases within the kidney (see "[Aminoacylase-Catalyzed Deacetylation of Mercapturic Acids](#s0155){ref-type="sec"}" section). The major interorgan pathways involved in the disposition of mercapturate and mercapturate intermediates are shown in [Fig. 3](#f0020){ref-type="fig"} .Fig. 3Interorgan processing of intermediates in the mercapturate pathway in mammals. The relative contribution of various organs to the generation of each component will depend in part on (1) tissue distribution of enzymes involved (which in turn may depend on species and gender), (2) relative transport systems (not shown), and (3) the nature of the electrophile. *X*, xenobiotic or endogenous electrophile; *XSG*, glutathione *S*-conjugate; *XSC*, cysteine *S*-conjugate; and *NAcXSC*, *N*-acetyl-cysteine *S*-conjugate (mercapturate). For additional details, see [@bib0935], [@bib0960], [@bib1000], [@bib1005], [@bib1010], [@bib1015], [@bib1115], [@bib1120], [@bib1990], and [@bib1810].

Work over the last two decades has established the importance of members of the ATP-binding cassette (designated ABC for human transporters and abc for rat transporters) superfamily for the cellular efflux of GSH, GSSG, glutathione *S*-conjugates, and other conjugated metabolites. As reviewed by [@bib0390], the ABC family in humans contains 49 members organized into seven subfamilies (A--G). Probably, the most important glutathione *S*-conjugate transporters are multidrug resistance protein 1 (MRP1, ABCC1) and MRP2 (ABCC2) ([@bib0390], [@bib1670], [@bib1985], [@bib2015], [@bib0385]). The ABCC2 transporter is important for the transport of LTC~4~ ([@bib1090], [@bib1670], [@bib1850]). Additional ABCC members, including long MRP6, short MRP4, MRP5, and MRP8, may also be involved in GSH and glutathione *S*-conjugate efflux ([@bib0390]). Interestingly, there are several mechanisms by which GSH may be involved in the ABCC1-catalyzed ATP-dependent transport of various compounds directly out of the cell: (1) transport of the glutathione *S*-conjugate, including LTC~4~, (2) GSH-stimulated egress (e.g., vincristine), and (3) GSH-stimulated efflux of the glutathione *S*-conjugate (e.g., the glutathione *S*-conjugate of nitroquinoline 1-oxide) (reviewed by [@bib0390]). The ABCC1 protein also catalyzes transport of GSSG and apigenin-stimulated GSH transport ([@bib0390]).

ABCC2 is localized to the apical membranes of various polarized cells involved in the secretion of conjugates derived from endogenous and xenobiotic substances. [@bib1670] present evidence that ABCC2 is the major transporter for the elimination of glutathione *S*-conjugate, glucuronic acid conjugate and sulfate conjugate of various toxins and carcinogens from hepatocytes into the bile, from kidney proximal tubule cells into urine, and from intestinal epithelial cells into the intestinal lumen. ABCC1 may be relatively more important in terminal detoxification in nonpolarized cell types ([@bib1670]).

Bile secretion results from the vectorial transport of solutes at the basolateral (sinusoidal) and apical (canalicular) membranes of liver parenchymal cells ([@bib1265]). The transcellular transport of solutes is dependent on the hydration state of the liver. Thus, bile formation is an important factor in liver osmoregulation. Solutes excreted into the bile by appropriate canalicular transporters include bile acids, glucuronides, and glutathione *S*-conjugates ([@bib1265]). Thus, glutathione *S*-conjugate secretion plays a useful role in liver osmoregulation and in the removal of potentially harmful xenobiotics.

[@bib0130] showed that RLIP76, a 76-kDa Ral-binding, Rho/Rac-GAP and Ral effector protein, is a transporter of several xenobiotics and glutathione *S*-conjugates. RLIP bears no homology to the ABC transporters. Glutathione *S*-conjugates of lipid peroxidation products are transported by RLIP76. The authors suggest that the transporter plays an important role as a resistance mechanism for preventing apoptosis caused by chemotherapeutic agents and a variety of external/internal stressors, including oxidative stress, heat shock, and radiation ([@bib0130]).

Recently, it was shown that MRP1, 4, and 5 are expressed in the lens, and it was suggested that these proteins are important in the detoxification of potentially toxic metabolites via excretion of the corresponding glutathione *S*-conjugates ([@bib2220]). Evidently, transporters are crucial factors in the detoxification/removal of endogenous and exogenous electrophiles via the mercapturate pathway.

10.17.4. Biotransformations of Endogenous Compounds through the Mercapturate Pathway {#s0100}
====================================================================================

10.17.4.1. Deactivation/Detoxification {#s0105}
--------------------------------------

The most well-characterized example of the involvement of the mercapturate pathway in the metabolism of endogenous compounds relates to the sequential transformations of leukotrienes: LTA~4~  → LTC~4~ (glutathione *S*-conjugate) → LTD~4~ (cysteinylglycine *S*-conjugate) → LTE~4~ (cysteine *S*-conjugate) by the consecutive actions of LTC~4~ synthase, γ-glutamyl leukotrienase, and cysteinylglycine dipeptidase ([@bib0045], [@bib0815], [@bib0930], [@bib1615], [@bib1715], [@bib2290]). LTE~4~ (along with LTC~4~ and LTD~4~) is the slowly reacting substance causing anaphylaxis. LTE~4~ is a potent stimulator of renal blood flow and glomerular filtration ([@bib0085], [@bib0805]). LTC~4~ and LTD~4~ are rapidly converted to LTE~4~ in vivo ([@bib1585]). LTE~4~ is deactivated in vivo by conversion to the *N*-acetyl derivative (mercapturate) in the kidney tubules and is excreted ([@bib0690]).

LTC~4~ synthase is a member of the GST family that is not involved in detoxification per se but rather catalyzes an important biosynthetic reaction ([@bib0045]). LTC~4~ synthase is present in eosinophils, mast cells, monocytes, neutrophils, and macrophages ([@bib2020]). The mouse and human LTC~4~ synthases have been characterized ([@bib2020]). LTC~4~ synthase is a membrane-bound enzyme (homodimer, subunit *M* ~r~ 18 × 10^3^) that shares some homology with microsomal GST-1 and GST-3 ([@bib1270]). The terminus contains a protein kinase C consensus phosphorylation sequence, raising the possibility that the enzyme is phosphoregulated. It has recently been suggested that drugs targeting LTC~4~ synthase may be beneficial for treatment of inflammatory diseases associated with overexpression of this enzyme ([@bib1195]).

LTC~4~ is formed intracellularly, but LTD~4~ and LTE~4~ are formed extracellularly by the action of the transferase and dipeptidase on the cell surface. Most effects of the leukotrienes are exerted via interactions with specific receptors on the cell surface ([@bib1040]). Two cell membrane receptors have been well characterized, namely, CysLT1 (synonyms, cysteinyl leukotriene receptor 1, cysteinyl leukotriene D4 receptor, and LTD4 receptor) and CysLT2 ([@bib1135], [@bib2005]). CysLTR1 belongs to the G-protein coupled receptor 1 family. CysLT1 is the receptor that participates in cysteinyl leukotriene-mediated bronchoconstriction of individuals with and without asthma. Stimulation by LTD4 results in the contraction and proliferation of smooth muscle, edema, eosinophil migration, and damage to the mucus layer in the lung. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system.

The rank order of affinities for the leukotrienes is LTD4 (*K* ~d~ ∼ 1 nM) \> LTE4 = LTC4 (*K* ~d~ ∼ 10 nM) \> LTB4. The CysLT1 receptor is widely expressed with highest levels in spleen and peripheral blood leukocytes. Lower expression occurs in several tissues, such as the lung (mostly in smooth muscle bundles and alveolar macrophages), placenta, small intestine, pancreas, colon, and heart. Selective antagonists of the CysLT1 receptor, such as montelukast (Singulair), zafirlukast (Accolate), and pranlukast (Onon), are used in the treatment of asthma, asthma-related diseases, and a few nonasthma-related diseases ([@bib0685], [@bib1825], [@bib1955]).

LTC~4~ is transported from the intracellular space to the extracellular space by an ATP-dependent transporter with high affinity for LTC~4~ (110 nM) ([@bib1035], [@bib1040], [@bib1270], [@bib1925]). This transporter (the GS-X pump) is identical to the GSSG transporter. (GSSG is a special case of a glutathione *S*-conjugate.) In addition to the kidney route for metabolism of leukotrienes mentioned earlier, hepatobiliary transport also occurs, and this is mediated by the GS-X pump ([@bib1040]). It is now known that the LTC~4~ transporter is the MR1P1/ABCC1 transporter (*K* ~m~ ∼ 3 μM) ([@bib0390], [@bib1670]).

Additional endogenous metabolites carried by the MRP1 carrier include the glutathione *S*-conjugates of prostaglandin (PG)A2, 15-deoxy-Δ^12,14^-PGJ~2~, and hydroxynonenal ([@bib0390]).

10.17.4.2. Bioactivation {#s0110}
------------------------

Although the mercapturate pathway evolved for the detoxification of potentially harmful metabolites and xenobiotics, on occasion, the pathway may result in a toxification (or bioactivation) event. Two examples of bioactivation of endogenous compounds will be discussed here, namely, catecholamines and estrogens. Catecholamines are readily oxidized to potentially toxic *o*-quinones ([@bib2025], [@bib2030], [@bib2035], [@bib2280], [@bib2285]). These *o*-quinones react readily with GSH and cysteine to form catecholamine glutathione *S*-conjugates and cysteine *S*-conjugates, respectively, which may account for the low levels of GSH in the substantia nigra of Parkinson disease (PD) patients. The cysteine *S*-conjugates of DOPA, dopamine, and 3,4-dihydroxyphenylacetic acid are present in the human brain ([@bib2030]). Interestingly, the concentrations of these compounds are generally lower in many regions of human postmortem PD brain compared with control brain. However, the concentrations of these conjugates are significantly higher in the substantia nigra of the PD patients, suggesting that these compounds may contribute to the damage in this region of the brain in PD patients ([@bib2030]).

The brain has the capacity to convert the glutathione *S*-conjugate and cysteinyl *S*-conjugate of dopamine to the corresponding mercapturate ([@bib1960]). It has been suggested that the dopamine mercapturate augments dopaminergic neurodegeneration ([@bib1580]). Previously, Dryhurst and coworkers established that the mercapturate of dopamine and 5-*S*-cysteinyldopamine are potent neurotoxins. The neurotoxicity of 5-*S*-cysteinyl catecholamines may be due to their further oxidation to benzothiazine species, such as DHBT-1 (dihydrobenzothiazine-1-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2*H*-1,4-benzothiazine-3-carboxylic acid) ([@bib1960], [@bib1965], [@bib2280]). Dryhurst and coworkers have suggested that DHBT-1 can cross the outer mitochondrial membrane and irreversibly inhibit complex I ([@bib1365], [@bib1375]). The formation of DHBT-1 and other benzothiazine species requires the oxidation and intramolecular cyclization of 5-*S*-[l]{.smallcaps}-cysteinyldopamine ([@bib1365], [@bib1965]).

DHBT-1 is oxidized by an unknown enzyme in isolated mitochondria to several highly electrophilic compounds ([@bib1365], [@bib1375]). These compounds are potent respiratory complex I inhibitors in isolated mitochondrial preparations ([@bib1365], [@bib1375], [@bib1970]). Complex I components and activity are markedly decreased in PD brain, whereas complexes II--V activities are relatively spared ([@bib1450], [@bib1560], [@bib1920]). A common feature of many neurodegenerative diseases is a decline in cerebral energy metabolism. In PD brain, this decline is due in part to decreased complex I activity. However, disruption of other mitochondrial enzymes/complexes of cerebral energy metabolism (e.g., α-ketoglutarate dehydrogenase complex (KGDHC) and pyruvate dehydrogenase complex (PDHC)) may also contribute to decreased energy production in neurodegenerative disease (reviewed by [@bib0765], [@bib1180]). For example, KGDHC activity is decreased in PD brain ([@bib1565]). Interestingly, DHBT-1 and its electrophilic metabolites are potent inhibitors of KGDHC ([@bib1970]) and PDHC activity ([@bib1370]) in disrupted rat brain mitochondria, apparently via covalent modification of crucial cysteine residues.

A lifetime dose of unopposed estrogen is a significant risk factor for breast and uterine cancer (reviewed by [@bib0010]). Estrogens may act either by an "epigenetic" pathway in which DNA is not chemically altered or they may be metabolized to products that damage DNA ([@bib1570]). Catechols are major metabolic products of natural and synthetic estrogens. They are readily oxidized to the corresponding *o*-quinones, which in turn are converted to GSH adducts ([@bib1570], [@bib2335]). [@bib1570] suggested that these glutathione *S*-conjugates may be released from the liver ultimately to be accumulated in the kidney as the cysteinyl conjugates. The cysteine *S*-conjugates may (1) react directly with DNA, (2) generate reactive oxygen species, or (3) be further transformed to insoluble polymers (possibly involving cyclization reactions) that cause local irritation and cell proliferation ([@bib1570]). Some evidence suggests that quinones derived from estradiol and specific glutathione *S*-conjugates of estradiol are potent inhibitors of human GSTM1-1 and GSTA1-1 ([@bib0010]).

10.17.5. Metabolic Pathways Diverging From Mercapturate Biosynthesis {#s0115}
====================================================================

10.17.5.1. Deconjugation {#s0120}
------------------------

As related to the mercapturate pathway, deconjugation is defined as the removal of the intact cysteine-containing moiety (usually as GSH) from the thioether conjugate ([@bib2075]). In general, two reactions can occur: (1) a disproportionation reaction in which GSH is converted to GSSG with concomitant elimination of the xenobiotic substituent (RH) (Eq. [5](#fo0030){ref-type="disp-formula"}) or (2) hydrolytic cleavage of a thioester (Eq. [6](#fo0035){ref-type="disp-formula"}).$$\left. GSR + GSH\rightarrow{GSSG} + RH \right.$$ $$\left. GS\left( {CO} \right)R + H_{2}O\rightarrow GSH + {RCOOH} \right.$$

In other cases, the deconjugation may simply be due to reversal of the conjugation reaction; glutathione *S*-(and possibly cysteine *S*-) conjugates may then act as vehicles for the delivery of free xenobiotics and GSH throughout the body ([@bib1085]). Methyl isocyanate, mentioned earlier, is an example of a compound that is distributed throughout the body by reversible, glutathione *S*-conjugate formation. Other examples include unsaturated compounds, such as acrolein and crotonaldehyde. A recently described example in which a glutathione *S*-conjugate is formed by Michael addition across a reactive double bond followed by reversible cysteine *S*-conjugate formation involves (6)-shogaol. This compound is a putative chemopreventive agent present in ginger. It has recently been shown that the corresponding cysteine *S*-conjugate acts as a delivery system for (6)-shogaol to tissues and tumors ([@bib0365]).

[@bib0140] state that "it seems likely that many xenobiotics with carbamate, formamide, urea, or sulfonylurea functionalities will undergo metabolic transformation to reactive isocyanates and that reversible conjugation to the latter short-lived, potentially toxic intermediates with GSH may play an important role in mediating the disposition and adverse effects of the parent compounds in vivo."

10.17.5.2. Deconjugation Coupled to Reductive Dehalogenation {#s0125}
------------------------------------------------------------

An example of deconjugation coupled to reductive dehalogenation is the nonenzymatic attack of GSH on 2,4-dichlorophenylacetyl chloride (Eq. [7](#fo0040){ref-type="disp-formula"}) followed by reaction of the conjugate with a second GSH (Eq. [8](#fo0045){ref-type="disp-formula"}) catalyzed by *S*-phenacylglutathione reductase ([@bib1185]).$$\left. {ClCH}_{2}C\left( O \right)\left( {C_{6}H_{3}{Cl}_{2}} \right) + GSH\rightarrow{GSCH}_{2}C\left( O \right)\left( {C_{6}H_{3}{Cl}_{2}} \right) + HCl \right.$$ $$\left. {GSCH}_{2}C\left( O \right)\left( {C_{6}H_{3}{Cl}_{2}} \right) + GSH\rightarrow{CH}_{3}C\left( O \right)\left( {C_{6}H_{3}{Cl}_{2}} \right) + {GSSG} \right.$$

The rat liver enzyme catalyzes the reductive dehalogenation of *o*-chloroacetophenone, but not of benzyl halides, suggesting the need for the carbonyl to stabilize a carbanion intermediate ([@bib1185]). The enzyme is now known to be identical to GSTO1-1 ([@bib0235]). In addition to catalyzing GST reactions and *S*-(phenacyl)glutathione reduction, the enzyme also catalyzes thioltransferase reactions and reduction of dehydroascorbate and monomethylarsonate (V) ([@bib0235]).

A second example involves vicinal dihaloalkanes. Several vicinal dihaloalkanes have been used industrially. Many of these compounds are cytotoxic and mutagenic (reviewed by [@bib0090], [@bib0100]). In the presence of GSH and a liver GST preparation, these compounds are converted to glutathione *S*-conjugates and eventually to alkenes. Depending on the structure of the dihaloalkane, the mechanism may involve E2 elimination, substitution followed by elimination, or both ([@bib1400]). In the case of 1,2-dichloroethane and 1,2-dibromoethane, reaction of the dihaloalkane with GSH yields *S*-(2-haloethyl)glutathione and halide ion. There is evidence for the formation of an episulfonium intermediate (1-(glutathione-*S*-yl)thiiranium) from *S*-(2-haloethyl)glutathione as an intermediate in the formation of haloalkene ([@bib1400]). *S*-(2-Haloethyl)glutathione may be converted to the thioether cysteine *S*-conjugate (*S*-(2-haloethyl)-[l]{.smallcaps}-cysteine) by the action of GGT and dipeptidases. The loss of halide ion yields an episulfonium cysteine *S*-conjugate (1-(2-amino-2-carboxyethyl)thiiranium). 1-(Glutathione-*S*-yl)thiiranium is thought to be the species responsible for the mutagenicity of vicinal dihaloalkanes by forming an adduct (*S*-(2-(*N* ^7^-guanyl)-glutathione)) with DNA. 1-(2-Amino-2-carboxyethyl)thiiranium is thought to be the cytotoxic species (reviewed by [@bib0100]).

1,2-Dibromo-3-chloropropane was used for many years as a soil fumigant to control nematodes but was banned in the United States in 1977 because it was shown to induce infertility in men and tumors in experimental animals ([@bib0380]). The compound is converted to a glutathione *S*-conjugate with the loss of bromide at the 1 position, but in this case, deconjugation does not occur. The conjugate is converted to a thiiranium ion with the loss of a second bromide ion. This thiiranium ion is implicated in the testicular toxicity of 1,2-dibromo-3-chloropropane. Hydrolysis, formation of a second thiiranium ion, and a second hydrolysis yield chloride ion and *S*-(2,3-dihydroxypropyl)glutathione ([@bib0100]).

10.17.5.3. Hydrolytic Deconjugation {#s0130}
-----------------------------------

Perhaps the best-studied example occurs in the two-step glyoxalase detoxification reaction. In the first step, GSH forms an adduct with methylglyoxal (synonyms, 2-oxopropanal and pyruvaldehyde), a potentially toxic byproduct of glycolysis ([@bib0335], [@bib0080]), yielding the glutathione *S*-conjugate *S*-[d]{.smallcaps}-lactoylglutathione in a reaction catalyzed by glyoxalase I. This enzyme is a metalloglutathione *S*-transferase that catalyzes a 1,2 hydrogen transfer ([@bib0520]). In the second step, glyoxalase II catalyzes the hydrolytic cleavage of *S*-[d]{.smallcaps}-lactoylglutathione to free GSH and [d]{.smallcaps}-lactate (glyoxalase II reaction) ([@bib0510]). Mitochondria require GSH to maintain redox balance, yet GSH is made exclusively in the cytosol. While there are well-defined mitochondrial uptake systems for GSH ([@bib1475], [@bib0245]), it has recently been shown that *S*-[d]{.smallcaps}-lactoylglutathione is an alternative source of GSH in mitochondria ([@bib0125]). *S*-[d]{.smallcaps}-Lactoylglutathione is taken up by the mitochondria wherein it is hydrolyzed by glyoxalase II to D-lactate and GSH ([@bib0125]).

In the case of mammalian glyoxalase, both glutathione *S*-conjugate formation and hydrolytic cleavage are enzyme-catalyzed, and GSH is regenerated. In other cases of hydrolytic deconjugation, the initial formation of the glutathione *S*-conjugate is enzyme-catalyzed, but the subsequent hydrolysis occurs nonenzymatically. Examples include the net conversion of chloramphenicol to an aldehyde catalyzed by several GSTs (Eq. [9](#fo0050){ref-type="disp-formula"}) ([@bib1480], [@bib1485]) and dihalomethanes to formaldehyde ([@bib0055], [@bib0090], [@bib0100]) (Eq. [10](#fo0055){ref-type="disp-formula"}).$$\left. RNH\left( {CO} \right){CHCl}_{2} + H_{2}O\rightarrow RNH\left( {CO} \right)CHO + 2HCl \right.$$ $$\left. {CH}_{2}X_{2} + H_{2}O\rightarrow{CH}_{2}O + 2HX \right.$$

Trypanosomes have a two-enzyme system identical to the mammalian glyoxalase system, except that trypanothione (two glutathione moieties covalently bridged by spermidine) is used in place of GSH. Thus, the glyoxalase system in trypanosomes is a potential drug target ([@bib1995], [@bib2430], [@bib1455]).

Dichloromethane is mutagenic in some systems, and GSH is implicated in the bioactivation ([@bib0055], [@bib0100], [@bib1930]). GSH reacts with dichloromethane in a reaction catalyzed by GSTT1-1 to yield the corresponding glutathione *S*-conjugate (*S*-(chloromethyl)glutathione) and chloride. Hydrolysis affords *S*-(hydroxymethyl)glutathione. This compound is a hemithioacetal of formaldehyde and can release formaldehyde (Eq. [11](#fo0060){ref-type="disp-formula"}). The released formaldehyde may account for the mutagenicity of dichloromethane, but model compounds also suggest a possible role for *S*-(chloromethyl)glutathione.$$\left. {HCHO} + GSH\rightleftarrows{GSCH}_{2}OH \right.$$

Formaldehyde GSH hemithioacetal is oxidized to *S*-(formyl)glutathione by a dehydrogenase (Eq. [12](#fo0065){ref-type="disp-formula"}). Hydrolytic cleavage of the latter (a thioester) by *S*-formylglutathione hydrolase yields formic acid and GSH (Eq. [13](#fo0070){ref-type="disp-formula"}) ([@bib2225]).$$\left. {GSCH}_{2}OH + {NAD}^{+}\rightarrow{GSCHO} + {NADH} + H^{+} \right.$$ $$\left. {GSCHO} + H_{2}O\rightarrow GSH + {HCOOH} \right.$$

10.17.5.4. Bis(glutathionyl) Conjugate Formation {#s0135}
------------------------------------------------

Trypanothione, mentioned earlier, is a bis-glutathionylated derivative of spermidine. In other cases, some xenobiotics have been shown to undergo metabolic transformations that result, in part, in the formation of bis(glutathionyl) conjugates. Examples include sulfur mustards ([@bib0565]), melphalan ([@bib0635]), hexachlorobutadiene ([@bib1105]), bromobenzene ([@bib1575]), chloroform ([@bib1775]), and bromotrichloromethane ([@bib1775]). The bis(conjugate) arises from an attack of a second GSH on an electrophilic center on the monoglutathionyl conjugate. The reaction may be nonenzymatic, but in most cases, the nature of the reaction is unknown. The mechanism of bis(glutathionyl) adduct formation with bromobenzene is complex. Bromobenzene can be converted to several products in vivo, but in one pathway in rats, it is sequentially oxidized to *o*-bromophenol, 2-bromohydroquinone, and 2-bromoquinone. 2-Bromoquinone is subject to attack by GSH at any one of three places on the ring, yielding three possible positional isomers. These isomers can then react further with another molecule of GSH to yield 2-bromo-3,5-(diglutathion-*S*-yl)-hydroquinone or 2-bromo-3,6-(diglutathion-*S*-yl)-hydroquinone ([@bib1575]). In the case of hexachlorobutadiene, microsomal GST catalyzes GSH adduct formation with elimination of HCl. A second addition of GSH and elimination of HCl yield the bis(conjugate) ([@bib1575]). In a similar reaction, dibromoethane is converted to the diconjugate in the rat liver (Eq. [14](#fo0075){ref-type="disp-formula"}) ([@bib1620]).$$\left. {BrCH}_{2}{CH}_{2}Br\  + \ 2GSH\rightarrow{GSCH}_{2}{CH}_{2}SG + 2HBr \right.$$

Haloforms are oxidized in a cytochrome P450-catalyzed reaction to trihalomethanol followed by dehydrohalogenation to yield a dihalocarbonyl (Eqs. [15](#fo0080){ref-type="disp-formula"} and [16](#fo0085){ref-type="disp-formula"}). Sequential attack by two GSH equivalents yields *S*-haloformylglutathione (Eq. [17](#fo0090){ref-type="disp-formula"}) and the dithiocarbonate (Eq. [18](#fo0095){ref-type="disp-formula"}). The net reaction is given by Eq. [(19)](#fo0100){ref-type="disp-formula"}. In addition, the *S*-haloformylglutathione conjugate may also undergo oxidative deconjugation to yield carbon monoxide (Eq. [20](#fo0105){ref-type="disp-formula"}) ([@bib2065], [@bib2070]).$$\left. {CX}_{3}H + O_{2} + {NADPH} + H^{+}\rightarrow{CX}_{3}OH + H_{2}O + {NADP}^{+} \right.$$ $$\left. {CX}_{3}OH\rightarrow{CX}_{2}O + HX \right.$$ $$\left. GSH + {CX}_{2}O\rightarrow GS\left( {CO} \right)X + HX \right.$$ $$\left. GS\left( {CO} \right)X + GSH\rightarrow GS\left( {CO} \right)SG + HX \right.$$ $$\left. {CX}_{3}H\  + \ O_{2} + {NADPH}\  + \ 2GSH\  + \ H^{+}\rightarrow GS\left( {CO} \right)SG\  + \ H_{2}O\  + \ {NADP}^{+} + \ 3HX \right.$$ $$\left. GS\left( {CO} \right)X + GSH\rightarrow CO + {GSSG} + HX \right.$$

10.17.5.5. Deamination and Transamination {#s0140}
-----------------------------------------

DCVC is oxidized to the corresponding α-keto acid by rat kidney [l]{.smallcaps}-amino acid oxidase ([@bib2080]; Eq. [21](#fo0110){ref-type="disp-formula"}). Conversion of a cysteine *S*-conjugate to the corresponding α-keto acid also occurs by transamination with a suitable α-keto acid acceptor (Eq. [22](#fo0115){ref-type="disp-formula"}; [@bib0415], [@bib0490], [@bib0500], [@bib2080]).$$\left. {RSCH}_{2}CH\left( {{NH}_{3}}^{+} \right){{CO}_{2}}^{-} + O_{2} + H_{2}O\rightarrow{RSCH}_{2}C\left( O \right){{CO}_{2}}^{-} + H_{2}O_{2}{{+ NH}_{4}}^{+} \right.$$ $$\left. {RSCH}_{2}CH\left( {{NH}_{3}}^{+} \right){{CO}_{2}}^{-} + R^{\prime}C\left( O \right){{CO}_{2}}^{-}\rightleftarrows{RSCH}_{2}C\left( O \right){{CO}_{2}}^{-} + R^{\prime}CH\left( {{NH}_{3}}^{+} \right){{CO}_{2}}^{-} \right.$$

The α-keto acid generated either by the action of [l]{.smallcaps}-amino acid oxidase or via transamination may be reduced to the corresponding α-hydroxy acid (Eq. [23](#fo0120){ref-type="disp-formula"}). Alternatively, the α-keto acid may be oxidatively decarboxylated in a reaction analogous to the PDHC reaction (Eq. [24](#fo0125){ref-type="disp-formula"}).$$\left. {RSCH}_{2}C\left( O \right){{CO}_{2}}^{-} + {NADH} + H^{+}\rightleftarrows{RSCH}_{2}CH\left( {OH} \right){{CO}_{2}}^{-} + {NADH}^{+} \right.$$ $$\left. {RSCH}_{2}C\left( O \right){{CO}_{2}}^{-} + {NAD}^{+} + H_{2}O\rightleftarrows{RSCH}_{2}{{CO}_{2}}^{-} + {CO}_{2} + \ {NADH} + H^{+} \right.$$

It is not clear how important these side reactions are to the metabolism of most cysteine *S*-conjugates in the intact animal, but there is no doubt that they do occur in vivo with some cysteine *S*-conjugates. For example, methylthioacetate and methylthiolactate are urinary metabolites of *S*-methyl-[l]{.smallcaps}-cysteine in the rat ([@bib0165], [@bib0975]). The methyl group of *S*-methyl-[l]{.smallcaps}-cysteine is eventually oxidized to CO~2~ ([@bib0975]). *S*-Methyl-[l]{.smallcaps}-cysteine is a good aminotransferase substrate of cytosolic rat kidney ([@bib0435], [@bib0440]) and human ([@bib0490]) glutamine transaminase K (GTK). The transamination product is expected to be a precursor of methylthiolactate and methylthioacetate. After administration of *S*-pentyl-[l]{.smallcaps}-cysteine to rabbits, the corresponding α-hydroxy acid and α-keto acid metabolites were found in the urine ([@bib1075]). Inorganic sulfate and dicarboxy methyl sulfide are formed in humans and experimental animals administered *S*-carboxymethylcysteine ([@bib2185]).

10.17.5.6. Sulfur Oxidation of Components of the Mercapturate Pathway {#s0145}
---------------------------------------------------------------------

In some cases, oxidation of the sulfur of the conjugates in the mercapturate pathway to sulfoxides and sulfones occurs in vivo. For example, methylsulfonylacetate, *S*-methylsulfonylthiolacetate, and methylmercapturate sulfoxide are metabolites of *S*-methyl-[l]{.smallcaps}-cysteine in rats ([@bib0165], [@bib0975], [@bib2010]). *S*-Methylcysteine sulfoxide and the sulfoxides of methylthiolacetate and methylmercapturate are found in the urine of humans administered *S*-methyl-[l]{.smallcaps}-cysteine ([@bib1545]). After administration of propachlor to normal rats, the sulfoxide of the corresponding mercapturate is a minor metabolite ([@bib0695]). However, after treatment with antibiotics, a considerable fraction (17%) of the dose was recovered as the sulfoxide of the mercapturate, suggesting that microbial transformations in the gut may be important routes for the metabolism of certain sulfur-containing compounds.

In some cases, the sulfur of the cysteine *S*-conjugate may be oxidized by flavin-dependent monooxygenases (FMOs), but in other cases, the oxidation of the sulfur may occur after release of a thiol by a β-lyase reaction and thiomethylation (see the next section). In a few cases, a cysteine *S*-conjugate sulfoxide has been shown to be a substrate of purified cysteine *S*-conjugate β-lyases yielding pyruvate and ammonium ion ([@bib1290], [@bib2160]). The sulfur-containing fragment initially released in this process is presumably a sulfenic acid (RS(O)H).

Elfarra and coworkers have shown that the sulfoxide of DCVC, like DCVC itself, is nephrotoxic ([@bib1025], [@bib1330], [@bib1340], [@bib1830], [@bib1900], [@bib1905]) and mutagenic ([@bib1025]). The corresponding mercapturate is also nephrotoxic ([@bib1030]). The cysteine *S*-conjugate sulfoxide of tetrachloroethylene ((*S*-(1,2,2-trichlorovinyl)-[l]{.smallcaps}-cysteine, TCVC) was also shown to be nephrotoxic. The toxicity, however, does not appear to be due to a β-elimination of a sulfenic acid ([@bib0650]). Elfarra and coworkers have characterized an FMO from rat liver and kidney microsomes that has high activity toward the cysteine *S*-conjugate *S*-benzyl-[l]{.smallcaps}-cysteine and that appears to be related to known flavin monooxygenase 1A1 isozymes ([@bib1830], [@bib1905]).

A number of mercapturates derived from halogenated alkenes are converted to the corresponding sulfoxides by cytochrome P450 3A (but apparently not by FMOs) ([@bib0220], [@bib2345], [@bib2350], [@bib2355]). These sulfoxides are nephrotoxic, but the exact mechanism remains to be elucidated (reviewed by [@bib0100]). Part of the nephrotoxicity of DCVC, however, may be due to sulfoxide formation in vivo and subsequent Michael addition at the terminal carbon of the vinyl group by a suitable nucleophile. The nucleophile may be GSH. Indeed, *S*-(1-chloro-2-(*S*-glutathionyl)vinyl)-[l]{.smallcaps}-cysteine sulfoxide, formed by Michael addition of GSH and elimination of HCl, was detected in the bile of rats treated with DCVC sulfoxide. There was a marked decrease of hepatic GSH, which may have been depleted during the formation of the sulfoxide ([@bib1900]). Some drugs (e.g., certain mustards) are also converted to mercapturate sulfoxides that are found in human bile ([@bib0175], [@bib2135]).

10.17.5.7. Thiomethyl Shunt {#s0150}
---------------------------

As already noted, many cysteine *S*-conjugates that contain a good leaving group are converted to pyruvate, ammonium ion, and a compound with a free thiol by cysteine *S*-conjugate β-lyases. In the thiomethyl shunt, the thiol product is methylated by thiomethyltransferase ([@bib1070], [@bib2340]). *S*-Adenosylmethionine is the methyl donor. The resulting thiomethyl compound is then a substrate for enzymes, such as the FMOs that oxidize thioethers to sulfoxides and sulfones ([@bib2480]). Further oxidation of the eliminated fragment could account for the formation of ^14^CO~2~ and inorganic sulfate from ^14^C-methyl-labeled *S*-methyl-[l]{.smallcaps}-cysteine ([@bib0975]).

Additionally, one other pathway that may lead to inorganic sulfate formation has been described. The cysteine *S*-conjugate is converted to the corresponding methyl sulfoxide. This compound is then reacted with GSH to yield the original glutathione *S*-conjugate and methane sulfenic acid (Eq. [25](#fo0130){ref-type="disp-formula"}), which is oxidized to CO~2~ and sulfate ([@bib0150]).$$\left. RS\left( O \right){Me} + GSH\rightarrow HS\left( O \right){Me} + GSR \right.$$

10.17.5.8. Aminoacylase-Catalyzed Deacetylation of Mercapturic Acids {#s0155}
--------------------------------------------------------------------

Aminoacylases catalyze the hydrolysis of mercapturates to cysteine *S*-conjugates and acetate. A brief discussion of these enzymes is included here because even though mercapturates are usually detoxification end products, the mercapturate itself can sometimes be toxic, for example, in the case of mercapturates derived from halogenated alkenes ([@bib0240], [@bib0410], [@bib1655]). Relative toxicity of these mercapturates to the kidney and other organs depends in part on the comparative activities of cysteine *S*-conjugate β-lyases, cysteine *S*-conjugate acetyltransferase, and cysteine *S*-conjugate aminoacylases. The halogenated cysteine *S*-conjugates, but not the corresponding mercapturates, are bioactivated by β-lyases ("[Background: Bioactivation of Halogenated Alkenes](#s0165){ref-type="sec"}" section).

Several mammalian aminoacylases have been described, including aminoacylase I (AAI, *N*-acyl amino acid hydrolase), aminoacylase II (AAII, aspartoacylase, *N*-acyl-[l]{.smallcaps}-aspartate amidohydrolase), acyllysine deacylase (*N* ^ϵ^-acyl-[l]{.smallcaps}-lysine amidohydrolase), and aminoacylase III ([@bib0105], [@bib1655]). AAI can catalyze the deacetylation of several *N*-acetylated amino acids, of which *N*-acetyl-[l]{.smallcaps}-methionine is the best substrate. The enzyme also catalyzes the deacetylation of mercapturates derived from halogenated alkenes ([@bib0105], [@bib0750], [@bib0755], [@bib0920], [@bib1215], [@bib1220], [@bib2230], [@bib2235], [@bib2240]). AAI activity toward haloalkene-derived mercapturates is widespread in mammalian tissues ([@bib2245]). The enzyme has been cloned from porcine, bovine, and rat tissues ([@bib1065], [@bib1550], [@bib1745], [@bib1805]). The amino acid sequence of human AAI has been deduced from the cDNA ([@bib1555]). Rat kidney, but not pig kidney, appears to contain two isoforms ([@bib1745]). Pig kidney AAI shows strong sequence homology to renal dipeptidase and is now assigned to the M20 peptidase family ([@bib1395]). Pig kidney AAI, like the dipeptidase, is attached to membranes ([@bib0920]).

The bovine enzyme is a homodimer (812 amino acids per monomer) containing one zinc atom per monomer and no disulfide bonds ([@bib1220], [@bib1390], [@bib1395]). The major physiological function is unclear, although it has been suggested to act on the terminal *N*-acetyl amino acids released by hydrolysis of peptides containing an N-terminal acetyl amino acid catalyzed by acylamino acid-releasing enzyme. It has not yet been possible to crystallize the enzyme. Nevertheless, [@bib1395] were able to construct a useful homology model based on the known 3-D structures of several members of the M20 peptide family, site-directed mutagenesis, and docking studies with *N*-acetyl-[l]{.smallcaps}-cysteine. Previous workers suggested that the zinc ion was needed to hold the enzyme in the correct configuration but was not involved in catalysis. However, [@bib1395] have presented a newer model for the catalytic reaction in which Glu146 functions as a general base, accepting a proton from zinc-bound water and shuttling the proton to the leaving group facilitating breakdown of the tetrahedral intermediate. Arginine 348 helps polarize the carbonyl of the acetyl group facilitating attack by hydroxide generating a tetrahedral intermediate.

AAIII is known to exhibit a preference for *N*-acetyl-[l]{.smallcaps}-aromatic amino acids. [@bib1655] showed that recombinant mouse AAIII exhibits high activity toward the *N*-acetyl derivatives of tyrosine, phenylalanine, tryptophan, histidine, and lysine (α-positional isomer) but is inactive toward the *N*-acetyl derivatives of cysteine, aspartic acid, and lysine (ε-positional isomer). The enzyme is, however, active toward the *N*-acetyl derivative of *S*-(benzyl)-[l]{.smallcaps}-cysteine, various substituted benzyl-[l]{.smallcaps}-cysteines, and at least eight cysteine *S*-conjugates derived from halogenated alkenes. Reported *V* ~max~/*K* ~m~ values for the toxic *N*-acetyl cysteine *S*-conjugates of halogenated alkenes were generally similar to those of the *N*-acetyl derivatives of the [l]{.smallcaps}-aromatic amino acids but in a few cases considerably higher ([@bib1655]).

AAIII has been less well studied than AAI. The mouse liver enzyme is a mixture of homodimers and homotetramers, both of which are active. A model of the dimer--tetramer interaction has been proposed ([@bib1880]). Recently, it was shown that inhibition of AAIII protects neuronal cells against the toxicity of 4-hydroxynonenal and 4-hydroxynonenal mercapturate ([@bib2180]).

It is interesting to note that the guinea pig kidney is especially vulnerable to the toxic effects of 2,3,5-(triglutathion-*S*-yl)hydroquinone. In the guinea pig, renal activity of microsomal *N*-acetyltransferase is lower than that in mouse and rat kidney, whereas activity of the deacylase is higher ([@bib1350]). The balance of *N*-deacetylase and *N*-acetylase in favor of the former in the guinea pig may contribute to the susceptibility of this species to 2,3,5-(triglutathion-*S*-yl)hydroquinone nephrotoxicity ([@bib1350]).

10.17.6. Cysteine *S*-Conjugate β-Lyases {#s0160}
========================================

10.17.6.1. Background: Bioactivation of Halogenated Alkenes {#s0165}
-----------------------------------------------------------

Haloalkenes (e.g., trichloroethylene, tetrachloroethylene, tetrafluoroethylene, and hexachloro-1,3-butadiene) are among several hundred potentially dangerous toxicants listed as present in Superfund sites in the United States. Part of the US population is exposed to haloalkenes from such sites and in the workplace ([@bib2425]) and possibly through "recreational" abuse ([@bib1470]). In experimental animals, haloalkenes, some halogenated alkanes, and dichloroacetylene are toxic, especially to the kidneys (e.g., [@bib0590], [@bib0640], [@bib1205]). In humans, heavy exposure to trichloroethylene is associated with an increased risk of cancer to the kidney ([@bib0250], [@bib1875], [@bib0070]) and possibly to the liver ([@bib0880], [@bib2305]), PD ([@bib0745]), and damage to the fifth cranial (trigeminal) nerve, sensory nucleus of the brainstem ([@bib0285]), and other nervous tissues ([@bib0375]). Cranial nerve damage appears to be associated with formation of dichloroacetylene from trichloroethylene exposed to an alkaline milieu. Dichloroacetylene is an exceptionally good substrate of microsomal GSTs (Eq. [2](#fo0015){ref-type="disp-formula"}) and hence is a good precursor of the toxic cysteine *S*-conjugate DCVC ([@bib1815]). Damage to the trigeminal nerve may be due to the toxic effects of DCVC or to activation of latent herpes virus by the toxic insult ([@bib0330]).

Trichloroethylene induces (1) aplastic anemia in cattle and (2) kidney damage in all animal species tested, including cattle ([@bib1410]). Depending on the structure, halogenated alkenes may be metabolized by cytochrome P450 isoenzymes (especially CYP2E1) and/or by GSTs. The ratio of the two activities varies considerably among the various halogenated alkenes. For example, hexachloro-1,3-butadiene ([@bib2330]) and tetrafluoroethylene ([@bib1675]) are metabolized predominantly in rats via glutathione *S*-conjugation. However, trichloroethylene and tetrachloroethylene are metabolized mainly by cytochrome P450s, and only a small portion is metabolized by GSTs (e.g., [@bib1205]), principally GSTA1-1 ([@bib0535]). Nevertheless, although the cytochrome P450 pathway generates toxic species from trichloroethylene and tetrachloroethylene ([@bib0275]), a major contributor to the overall toxicity of trichloroethylene and tetrachloroethylene is the corresponding cysteine *S*-conjugate despite the fact that the glutathione *S*-conjugation pathway is quantitatively minor ([@bib0580]).

The glutathione *S*-conjugate, cysteinylglycine *S*-conjugate, cysteine *S*-conjugate, and *N*-acetylcysteine *S*-conjugate (mercapturate) derived from halogenated alkenes are all nephrotoxic/hepatotoxic and in many cases nephrocarcinogenic/hepatocarcinogenic in experimental animals (e.g., [@bib0090], [@bib0100], [@bib0105], [@bib0110], [@bib0240], [@bib0575], [@bib0580], [@bib1205], [@bib1505], [@bib1345], [@bib2455], [@bib0525]). Some of these conjugates are also mutagenic in bacterial tester strains ([@bib0410], [@bib0620], [@bib0700], [@bib1250], [@bib2265], [@bib2270]). The cysteine *S*-conjugate formed from trichloroethylene/dichloroacetylene (i.e., DCVC) induces expression of the proto-oncogenes c-*fos* and c-*myc* in LLC-PK~1~ cells ([@bib2260], [@bib2275]). The mutagenicity depends on the ability of the conjugates to generate chemically reactive thiols; GGT and cysteine *S*-conjugate β-lyases are key enzymes in this process. As noted earlier, the mercapturates derived from the halogenated alkenes are toxic because they can be hydrolyzed back to the corresponding cysteine *S*-conjugate by aminoacylases (e.g., [@bib2245]). Thus, the mercapturate pathway enzymes together with aminoacylases and cysteine *S*-conjugate β-lyases contribute to the bioactivation of halogenated alkenes. (For reviews, see [@bib0090], [@bib0100], [@bib0425], [@bib0455], [@bib0500], [@bib0580], [@bib0590].) The reactive fragments generated from haloalkene cysteine *S*-conjugates by the action of cysteine *S*-conjugate β-lyases are especially cytotoxic in experimental animals to the proximal renal tubules, in particular to the S~3~ (*pars recta*) region and, to a lesser extent, the S~1~ and S~2~ (*pars convoluta*) region (e.g., [@bib1110]) and to isolated human proximal tubules ([@bib0350]).

10.17.6.2. Possible Repair Mechanisms {#s0170}
-------------------------------------

Cytosolic rat kidney cysteine *S*-conjugate β-lyase (or more accurately GTK) and its mRNA were shown to be elevated in the kidneys of rats given a single nonnephrotoxic dose of *N*-acetyl-*S*-(1,2,3,4,4-pentachloro-1,3-butadienyl)-[l]{.smallcaps}-cysteine ([@bib1435]). However, nephrotoxic doses resulted in reduction of the total lyase activity ([@bib1435]). This reduction may result in part from the fact that turnover of cysteine *S*-conjugates derived from halogenated alkenes can result in syncatalytic inactivation of cysteine *S*-conjugate β-lyases ("[Catalytic Mechanism of the Cysteine S-Conjugate β-Lyase Reaction and Syncatalytic Inactivation](#s0200){ref-type="sec"}" section). A reduction in the lyase activity could be a protective mechanism as long as the normal metabolic function of the lyase is not compromised too severely.

It has been shown that a lethal dose of DCVC in mice leads to inhibition of cell division, inhibition of renal repair, and acute renal failure ([@bib1225], [@bib2250], [@bib2255]). However, sublethal (priming) doses are autoprotective by stimulating cell division and renal repair ([@bib1230]). Acute renal failure in humans is associated with high morbidity and mortality rates. However, renal failure is potentially reversible if the patients are free of life-threatening complications. [@bib1235] have pointed out that the pathophysiology of DCVC-induced acute tubular necrosis followed by acute renal failure in mice and clinical acute renal failure in patients is similar. These authors carried out a proteomic study of this clinically relevant mouse model of priming with low doses of DCVC to afford later autoprotection to the kidney. Whole kidney homogenates from treated and untreated mice were analyzed on 2D gels, and spots were identified by mass spectrometry. Expression of eighteen common proteins was shown to be greatly altered in the treated mice, including some enzymes associated with energy metabolism and stress response proteins. Although the proteomic approach to understanding renal disease is in its infancy, this model suggests that biomarker development will be useful in a variety of toxicological paradigms ([@bib1235]).

10.17.6.3. The Cysteine *S*-Conjugate β-Lyase Reaction {#s0175}
------------------------------------------------------

Historically, [@bib0405] showed that benzothiazole-2-sulfonamide is converted in rats, rabbits, and dogs, not only to the corresponding mercapturate but also to 2-mercaptobenzothiazine in which the sulfur of the mercaptan moiety is derived from GSH. Later, Schultze and coworkers suggested that the toxicity of DCVC is associated with a "C---S" lyase reaction and formation of a reactive sulfur-containing species that adds to macromolecules, including proteins and nucleic acids (e.g., [@bib0115], [@bib0195], [@bib0200]). It was known for many years that several electrophilic xenobiotics (e.g., phenacetin, acetaminophen, and *N*-hydroxy-2-acetylaminofluorene) are thiomethylated in vivo. Thiomethylation was originally assumed to involve a sulfonium compound derived from methionine. However, [@bib0345] showed that conversion of 2-acetamido-4-chloromethylthiazole to 2-acetamido-4-methylthiomethylthiazole in rats involves the mercapturate pathway and thiomethylation.

The thiomethylation pathway (shunt) (see "[Thiomethyl Shunt](#s0150){ref-type="sec"}" section) for the detoxification of xenobiotics was first elucidated by Tateishi and colleagues. When bromazepam was administered to rats, the corresponding mercapturate and 6′-methylthiobromazepam were identified in the bile ([@bib2125]). [@bib2125] also showed that the thioether bond of the cysteine *S*-conjugates of 2,4-dinitrobenzene and bromobenzene is readily cleaved by an enzyme present in rat liver cytosol. Incubation of the purified enzyme with *S*-(2,4-dinitrophenyl)cysteine yielded pyruvate, ammonium ion, and 2,4-dinitrobenzenethiol. Incubation of the thiol product with a microsomal thiomethyltransferase and *S*-adenosylmethionine yielded the corresponding thiomethyl compound ([@bib2125]). [@bib2130] coined the name "cysteine conjugate β-lyase" to describe an enzyme that catalyzes β-elimination from a cysteine *S*-conjugate. The net cysteine *S*-conjugate β-lyase-catalyzed reaction is shown in Eq. [26](#fo0135){ref-type="disp-formula"}.$$\left. {XSCH}_{2}CH\left( {{NH}_{3}}^{+} \right){{CO}_{2}}^{-} + H_{2}O\rightarrow{CH}_{3}C\left( O \right){{CO}_{2}}^{-} + {{NH}_{4}}^{+} + XSH \right.$$

The actual products of the enzyme-catalyzed reaction are XSH and aminoacrylate $\left\lbrack {{CH}_{2} = CH\left( {{NH}_{3}}^{+} \right){{CO}_{2}}^{-}} \right\rbrack$. The latter undergoes nonenzymatic tautomerization to the α-imino $\left\lbrack {{CH}_{3}CH\left( {= {{NH}_{2}}^{+}} \right){{CO}_{2}}^{-}} \right\rbrack$ and subsequent hydrolysis to pyruvate (CH~3~CHOCO~2~ ^−^) and ammonium ion. When the eliminated sulfur-containing fragment (XSH) is stable (i.e., does not contain moieties that cause XSH to be converted to an extremely reactive electrophile), the ---SH group may be methylated as in the case of the sulfur-containing fragment derived from *S*-(2,4-dinitrophenyl)-cysteine ([@bib2125]; [Fig. 1](#f0010){ref-type="fig"}, reaction [8](#fo0045){ref-type="disp-formula"}; "[Thiomethyl Shunt](#s0150){ref-type="sec"}" section). The thiomethylated compound may also be oxidized to the sulfoxide and sulfone as described in "[Sulfur Oxidation of Components of the Mercapturate Pathway](#s0145){ref-type="sec"}" section. Alternatively, XSH may be glucuronidated as in the case of 2-benzothiazole derived from benzothiazolyl [l]{.smallcaps}-cysteine (BTC) ([@bib0645]; [Fig. 1](#f0010){ref-type="fig"}, reaction [9](#fo0050){ref-type="disp-formula"}). Mercapturates and *S*-glucuronides are readily excreted. Thiomethyl derivatives may be excreted intact or following further oxidation at the sulfur. The fate of chemically reactive XSH fragments is discussed in "[Reactive Sulfur-Containing Fragments Generated by β-Lyase Reactions Involving Halogenated Alkene Cysteine S-Conjugates](#s0195){ref-type="sec"} section."

10.17.6.4. Cysteine *S*-Conjugate β-Lyases in Enteric Bacteria {#s0180}
--------------------------------------------------------------

Several studies have shown that many enteric bacteria contain cysteine *S*-conjugate β-lyases ([@bib0185], [@bib1285], [@bib1290], [@bib1295], [@bib1885], [@bib2085], [@bib2155], [@bib2325]). *E*. *coli* tryptophanase (a "true" physiologically relevant β-lyase) and a cysteine *S*-conjugate β-lyase in an extract of *Eubacterium limosum* were shown to catalyze β-elimination reactions with the cysteine *S*-conjugates of *E*-2-hexenal and 2-hexenol ([@bib2325]). The cysteine *S*-conjugate β-lyases purified from *Fusobacterium necrophorum* ([@bib1295]) and *F*. *varium* ([@bib2155]) have been partially purified and characterized. The enzymes have *M* ~r~ values of 228 × 10^3^ and 70 × 10^3^ and require pyridoxal 5′-phosphate (PLP) as a cofactor. The enzyme from *F*. *necrophorum* catalyzes the C---S cleavage of the cysteine *S*-conjugate of propachlor, BTC, and 1,2-dihydro-1-hydroxy-2-cysteinylnaphthalene. The propachlor conjugate was shown to be converted to *N*-isopropylacetanilide, pyruvate, and ammonium ion. The enzyme from *F*. *varium* is most active with aromatic cysteine *S*-conjugates, but some activity is noted with simple alkyl conjugates. A highly purified cysteine *S*-conjugate β-lyase was obtained from *E*. *limosum* ([@bib1285]). The enzyme has a *M* ~r~ of about 75 × 10^3^ and is composed of two identical subunits. The enzyme is active with the cysteine *S*-conjugate of propachlor, *trans*-9-hydroxy-10-(*S*-([l]{.smallcaps}-cysteinyl))-9,10-dihydrophenanthrene, BTC, and DCVC. It is also moderately active with the simple alkyl cysteine conjugate *S*-ethyl-[l]{.smallcaps}-cysteine. The enzyme does not require added PLP but is inhibited by carbonyl reagents suggesting the presence of a carbonyl-containing cofactor. Of interest is the finding that the enzyme is active with cystathionine, djenkolic acid, lanthionine, and cystine, suggesting that the enzyme is similar to PLP-dependent cystathionine β- and γ-lyases. In contrast, the *F*. *necrophorum* and *F*. *varium* lyases do not exhibit activity with cystathionine. [@bib0185] showed that rat fecal contents and the purified *E*. *limosum* enzyme catalyze the conversion of the cysteine *S*-conjugate LTE~4~ to 5-hydroxy-6-mercapto-7,9-*trans*-11,14-*cis*-eicosatetraenoic acid. Interestingly, the enzyme can catalyze the conversion of β-chloroalanine to pyruvate and ammonia, but it is not inactivated in the process. Many PLP-containing enzymes that catalyze this elimination reaction are syncatalytically inactivated by aminoacrylate intermediate(s) formed during the elimination reaction ("[Catalytic Mechanism of the Cysteine S-Conjugate β-Lyase Reaction and Syncatalytic Inactivation](#s0200){ref-type="sec"}" section). Finally, the *E*. *limosum* enzyme exhibits high activity with the *S*-oxide of propachlor ([@bib1290]). Eliminated fragment is presumably a sulfenic acid \[RS(O)H\].

Gut bacteria are known to be important in catalyzing biotransformations of certain xenobiotics, including conjugate formation with GSH ([@bib0145]). The fact that cysteine *S*-conjugate β-lyase activity is widespread in enteric bacteria and that a major portion of cysteine *S*-conjugates are excreted into the bile suggests that the gut flora may be important for the incorporation of sulfur into some xenobiotics ([@bib1290]). Moreover, it appears that the cysteine *S*-conjugate β-lyases of the enteric bacteria have different substrate specificities than do the mammalian enzymes. For example, the cysteine *S*-conjugate of propachlor is a substrate for the enteric enzymes, but germ-free rats do not metabolize this compound ([@bib0145]). As noted earlier, certain sulfhydryl-containing fragments, such as that eliminated from DCVC, are exceptionally reactive and are likely to act locally. Whether cysteine *S*-conjugates, whose elimination products are very reactive, damage the gut and bile duct remains to be determined. Additionally, whether more stable thiol products generated from bacterial cysteine *S*-conjugates can be transported from the gut to other regions to exert toxic effects also remains to be evaluated ([@bib1290]).

10.17.6.5. Cysteine *S*-Conjugate β-Lyases in Mammals {#s0185}
-----------------------------------------------------

In the 1970s, [@bib2130] obtained a highly purified preparation of a cysteine *S*-conjugate β-lyase from the rat liver, but they did not identify it. The same group also obtained a highly purified preparation of a PLP-dependent cysteine *S*-conjugate β-lyase from the human liver ([@bib2160]). The human liver enzyme is active with *S*-arylcysteines but not with *S*-alkylcysteines. The enzyme, which catalyzes stoichiometric formation of pyruvate, ammonium ion, and *p*-bromophenylmercaptan from *S*-(*p*-bromophenyl)-[l]{.smallcaps}-cysteine, has a pH optimum of 8.5 and has a native *M* ~r~ of ∼ 88 × 10^3^. Interestingly, the enzyme is nine times more active with *S*-phenylcysteine sulfoxide than with *S*-phenylcysteine. The identity of this enzyme was also not established. Moreover, the specific activity of the purified enzyme with *S*-(*p*-bromophenyl)-[l]{.smallcaps}-cysteine is relatively low (12.3 nmol min^− 1^  mg^− 1^) compared with the specific activity exhibited by the most active cysteine *S*-conjugate β-lyases identified thus far ([Table 1](#t0010){ref-type="table"} ). Additionally, the cysteine *S*-conjugates of halogenated alkenes were not tested as substrates.Table 1Mammalian PLP-dependent enzymes with [l]{.smallcaps}-cysteine *S*-conjugate β-lyase activity[a](#tf0010){ref-type="table-fn"}β-Lyase substratesDCVCTFECBTCSyncatalytic inactivationCompeting transaminationApproximate specific activity (U/mg[b](#tf0015){ref-type="table-fn"})*Enzyme* (*cytosolic*)Kynureninase (R)+ND++ND0.25GTK/KAT I (R)[c](#tf0020){ref-type="table-fn"}++−−+0.6--6.4GTK/KAT I (H)+++−+8--40GTL/KAT III (m)++−−+0.5--1.1cytAspAT (R)++±+−0.04--0.16AlaAT (P)++++−0.004--0.06BCAT~*c*~ (H)++++−0.3--0.5*Enzyme* (*mitochondrial*)mitAspAT (R)+++++0.8--2.3BCAT~m~ (H)++−+−0.2--0.5AGAT II (R)+++++0.2GABA aminotransferase (P)ND+NDNDND0.016High-M~r~ β-lyase (R)[d](#tf0025){ref-type="table-fn"}+++−+1.0--1.2[^1][^2][^3][^4]

In the mid-1980s, kynureninase ([@bib2060]) and GTK (identical to kynurenine aminotransferase isozyme I, KAT I) ([@bib2080]) were identified as major cysteine *S*-conjugate β-lyases of rat liver and kidney cytosol, respectively (DCVC as substrate). Over the ensuing decades, many more mammalian cysteine *S*-conjugate β-lyases have been identified ([Table 1](#t0010){ref-type="table"}). All are PLP-containing enzymes and include (1) the cytosolic enzymes kynureninase, GTK/KAT I, cytosolic aspartate aminotransferase (cytAspAT), glutamine transaminase L (GTL)/KAT III, alanine aminotransferase (AlaAT), and cytosolic branched-chain aminotransferase (BCAT~c~) and (2) the mitochondrial enzymes mitochondrial aspartate aminotransferase (mitAspAT), mitochondrial branched-chain aminotransferase (BCAT~m~), alanine-glyoxylate aminotransferase isozyme II (AGAT II), and GABA aminotransferase (reviewed by [@bib0450], [@bib0455], [@bib0500]). In addition, high-*M* ~r~ β-lyases occur in both cytosolic and mitochondrial fractions of the rat kidney and, to a lesser extent, rat liver. High-*M* ~r~ forms in rat kidney cytosol and mitochondria contain GTK and mitAspAT, respectively ([@bib0500]). Of all the mammalian cysteine *S*-conjugate β-lyases identified thus far, human GTK has the highest inherent specific activity ([Table 1](#t0010){ref-type="table"}; [@bib0455], [@bib0500]).

10.17.6.6. Cysteine *S*-Conjugate β-Lyases in Other Organisms {#s0190}
-------------------------------------------------------------

Fungi are known to contain GST activity ([@bib0120], [@bib0615]) and cysteine *S*-conjugate β-lyase activity ([@bib0810], [@bib1975]). For example, *Mucor circinelloides* (formerly *M*. *javanicus*) converts 2,4-dichloro-1-nitrobenzene to the corresponding glutathione *S*-conjugate, cysteine *S*-conjugate, and mercapturate, as well as to 5-chloro-2-nitrobenzenethiol ([@bib0810], [@bib1975]). Evidently, the role of fungi in transforming environmental xenobiotics through the mercapturate and β-lyase pathways needs to be further evaluated.

Three species of parasitic helminths have been shown to contain cysteine *S*-conjugate β-lyase activity ([@bib0035]). A cysteine *S*-conjugate β-lyase was purified from the tapeworm *Moniezia expansa* and shown to copurify with an enzyme that exhibited AspAT activity ([@bib0040]).

3-Mercaptohexanol is an odor detected in passion fruit and in sauvignon blanc wines ([@bib2325]). 3-Mercaptohexanol was suggested to be derived from the cysteine *S*-conjugate of *E*-2-hexenal ([@bib2325]). A β-lyase reaction with this compound will release 3-mercaptohexenal, which may be reduced to the corresponding alcohol. An alternative route may occur, namely, reduction of the cysteine *S*-conjugate of *E*-2-hexenal to the cysteine *S*-conjugate of 2-hexenol, followed by a cysteine *S*-conjugate β-lyase-catalyzed elimination to yield directly 3-mercaptohexenol. Both pathways are feasible. A series of alkanoates of 3-methyl-3-sulfanylbutan-1-ol ((CH~3~)~2~C(SH)CH~2~CH~2~OC(O)R) and a series of alkanoates of 3-sulfanylhexan-1-ol (CH~3~CH~2~CH~2~CH(SH)CH~2~CH~2~OC(O)R) have been detected in the fruit peel of *Poncirus trifoliata* (a close relative of citrus) ([@bib2045]). The authors suggested that the origin of these volatile sulfur-containing compounds is via β-lyase reactions on the corresponding cysteine *S*-conjugates. Starkenmann and colleagues have documented the importance of cysteine *S*-conjugate β-lyases in the generation of mercaptans in plants, such as green peppers and allium vegetables, and in mouth bacteria ([@bib2040], [@bib2050], [@bib2055]).

The odor of human sweat may be enhanced by the action of skin bacteria. 3-Sulfanylhexan-1-ol, along with 2-methyl-3-sulfanylbutan-1-ol, 3-sulfanylpentan-1-ol and 3-methyl-3-sulfanylhexan-1-ol, has been identified as odiferous compounds in human sweat ([@bib1645]). It was suggested that the nonodoriferous precursors of the sulfanylalkanols are cysteine *S*-conjugates. In agreement with this hypothesis, the authors showed that cysteine *S*-conjugates of sulfanylalkanols are substrates of a cysteine *S*-conjugate β-lyase cloned from the skin bacterium *Corynebacterium striatum* Ax20 present in human axillary secretions ([@bib1645]). The enzyme responsible was identified as cystathionine β-lyase.

Alliinase, an enzyme found in garlic and other allium vegetables, catalyzes the β-elimination of allylsulfenic acid from [l]{.smallcaps}-alliin---a cysteine *S*-conjugate sulfoxide (Eqs. [27](#fo0140){ref-type="disp-formula"} and [28](#fo0145){ref-type="disp-formula"}; [@bib0445] and references quoted therein). Allylsulfenic acid is extremely reactive and forms the anhydride allicin in an aqueous medium. Allicin reacts with cysteine to form a series of cysteine *S*-conjugates. Several of these cysteine *S*-conjugates are β-lyase substrates of cystathionine γ-lyase ([@bib0445], [@bib0500]). In some cases, the eliminated product is a persulfide, which may be a source of sulfane (S^0^ or S^0^) sulfur, contributing to the anticancer properties of garlic ([@bib1765]).$$\begin{array}{l}
\left. {CH}_{2} = {CHCH}_{2}S\left( O \right){CH}_{2}CH\left( {{NH}_{3}}^{+} \right){{CO}_{2}}^{-} + H_{2}O\rightarrow{CH}_{3}C\left( O \right){{CO}_{2}}^{-} + {{NH}_{4}}^{+} + {CH}_{2} = {CHCH}_{2}S\left( O \right)H \right. \\
{L\text{-}{Alliin}\mspace{324mu}{Allylsulfenic}\ {acid}} \\
\end{array}$$ $$\begin{array}{l}
\left. 2{CH}_{2} = {CHCH}_{2}S\left( O \right)H\rightarrow{CH}_{2} = {CHCH}_{2}S\left( O \right){SCH}_{2}CH = {CH}_{2} + H_{2}O \right. \\
{\mspace{135mu}{Allicin}} \\
\end{array}$$

10.17.6.7. Reactive Sulfur-Containing Fragments Generated by β-Lyase Reactions Involving Halogenated Alkene Cysteine *S*-Conjugates {#s0195}
-----------------------------------------------------------------------------------------------------------------------------------

A few examples will be provided here; for a more detailed coverage, see [@bib0100]. The cysteine *S*-conjugate β-lyase reaction with DCVC (**1**) gives rise to pyruvate (**2**), ammonium ion, and a sulfur-containing fragment that has the theoretical structure 1,2-dichloroethylenethiolate (**3**) ([Fig. 4](#f0025){ref-type="fig"} ). However, 1,2-dichloroethylenethiolate is extremely unstable and may tautomerize to chlorothioacetyl chloride \[ClC(S)CH~2~Cl\] (not shown) or spontaneously lose Cl^−^ to form the highly reactive chlorothioketene (**4**) ([@bib0090], [@bib0100] and references cited therein). The chlorothioketene reacts with a variety of nucleophiles (Nu:) to generate a thioacylated adduct (**5**). In biological systems, the nucleophile may be macromolecules, such as nucleic acids ([@bib1610]) and proteins ([@bib0675]). This chemistry provides an explanation for the previous finding of [@bib0115], who, as noted earlier, showed covalent incorporation of a sulfur-containing fragment from DCVC to macromolecules via the action of "C---S" lyases.Fig. 4Bioactivation of *S*-(1,2-dichlorovinyl)-[l]{.smallcaps}-cysteine (DCVC) by cysteine *S*-conjugate β-lyases. DCVC (**1**) is converted to pyruvate (**2**), ammonium ion, and a sulfur-containing fragment that has the theoretical structure 1,2-dichloroethylenethiolate (**3**). 1,2-Dichloroethylenethiolate is unstable and in part loses HCl to form the highly reactive chlorothioketene (**4**). The thioketene reacts with tissue nucleophiles (Nu:) to generate thioacylated products (**5**). Based in part on [@bib0090], [@bib0100].Reproduced from Cooper, A.J.L., Pinto, J.T., 2008. In Elfarra, A.A. (ed.), Biotechnology: Pharmaceutical Aspects. Advances in Bioactivation Research. Springer, New York, NY. pp. 323--346 with permission from Springer.

Cysteine *S*-conjugate β-lyase-catalyzed bioactivation of *S*-(1,1,2,2-tetrafluoroethyl)-[l]{.smallcaps}-cysteine (TFEC, the cysteine *S*-conjugate of tetrafluoroethylene) is shown in [Fig. 5](#f0030){ref-type="fig"} . The β-lyase reaction with TFEC (**1**) results in the formation of pyruvate (**2**), ammonium ion, and 1,1,2,2-tetrafluoroethanethiolate (**3**). 1,1,2,2-Tetrafluoroethanethiolate is very reactive, losing F^−^ to generate difluorothioacetyl fluoride (**4**), which thioacylates nucleophiles. ^35^S-Labeling studies performed in vivo show that phosphatidylethanolamine is a major small-molecular-weight nucleophile thioacylated in mitochondria by the action of cysteine *S*-conjugate β-lyases on TFEC ([@bib0910]). The ε-amino group of protein lysyl moieties is also especially vulnerable to thioacylation by **4** ([@bib0715], [@bib0885], [@bib0900], [@bib0905]).Fig. 5Bioactivation of *S*-(1,1,2,2-tetrafluoroethyl)-[l]{.smallcaps}-cysteine (TFEC) by cysteine *S*-conjugate β-lyases. TFEC (**1**) is converted to pyruvate (**2**), ammonium ion, and a sulfur-containing fragment that has the structure 1,1,2,2-tetrafluoroethanethiolate (**3**). 1,1,2,2-Tetrafluoroethanethiolate (**3**) is unstable and loses F^−^ to form difluorothioacetyl fluoride (**4**). Difluorothioacetyl fluoride reacts with tissue nucleophiles (Nu:) to generate thioacylated products (**5**). Based in part on [@bib0090], [@bib0100].Reproduced from Cooper, A.J.L., Pinto, J.T., 2008. In Elfarra, A.A. (ed.), Biotechnology: Pharmaceutical Aspects. Advances in Bioactivation Research. Springer, New York, NY. pp 323--346 with permission from Springer.

Bromine-containing 1,1-difluoroalkene-derived cysteine *S*-conjugates are nephrotoxic, but unlike the nonbrominated analogs, these compounds are also mutagenic in the Ames test ([@bib0700]). Initial studies with the cysteine *S*-conjugate of 1-bromo-2-chloro-1,1-difluoroethene with a rat kidney homogenate and a pyridoxal model system showed formation of glyoxylate as a product ([@bib0705]). The eliminated sulfur-containing fragment (1,1-difluoro-2-bromo-2-chloroethanethiolate) was suggested to undergo conversion to a three-membered ring structure (3-chloro-α-thiolactone) with the loss of F^−^ and Br^−^. The 3-chloro-α-thiolactone was then proposed to undergo conversion to glyoxylate by hydrolysis and the loss of Cl^−^ and H~2~S ([@bib0705]). Later work from the same group using *o*-phenylenediamine as a trapping agent suggested that a thiirane \[2,2-difluoro-3-chlorothiane\] was a likely intermediate in the decomposition of 1,1-difluoro-2-bromo-2-chloroethanethiolate ([@bib0100], [@bib0710]).

Sevoflurane \[(F~3~C)~2~COCH~2~F\] is a widely used anesthetic, which may lose HF in the anesthetic circuit to generate 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (Compound A), which is nephrotoxic to rats ([@bib0095]). In the rat, Compound A can form two glutathione *S*-conjugates, which are eventually converted to the corresponding cysteine *S*-conjugates. These cysteine *S*-conjugates are substrates of cysteine *S*-conjugate β-lyases giving rise to 2-(fluoromethoxy)-1,1,3,3,3-pentafluoropropanethiol and 2-(fluoromethoxy)-1,3,3,3-tetrafluoro-1-propenethiolate, both of which are converted to 2-(fluoromethoxy)-3,3,3-trifluorothionopropanoyl fluoride. Hydrolysis and the loss of HF and H~2~S yields 2-(fluoromethoxy)-3,3,3-trifluoropropanoic acid. Finally, the loss of HF and HCHO yields trifluoroacetic acid. Evidence suggests that a similar pathway for the metabolism of Compound A exists in humans. The pathway indicates that cysteine *S*-conjugate β-lyases are involved in the bioactivation of Compound A in humans, but this hypothesis has been criticized. Moreover, there are no confirmed cases of sevoflurane-induced kidney damage in humans. See [@bib0100] for a comprehensive review and original references.

10.17.6.8. Catalytic Mechanism of the Cysteine *S*-Conjugate β-Lyase Reaction and Syncatalytic Inactivation {#s0200}
-----------------------------------------------------------------------------------------------------------

[Table 1](#t0010){ref-type="table"} reveals that, with the possible exception of cystathionine γ-lyase, no mammalian cysteine *S*-conjugate β-lyase identified thus far catalyzes a β-lyase reaction as its "natural" physiological reaction. Although cystathionine γ-lyase normally catalyzes a γ-elimination reaction, it can also catalyze β-elimination reactions that may be physiologically relevant. For example, rat liver cystathionine γ-lyase catalyzes (1) the formation of *S*-mercapto-[l]{.smallcaps}-cysteine from [l]{.smallcaps}-cystine ([@bib0320]), (2) β-elimination of alkane thiols from several nonhalogenated cysteine *S*-conjugates containing alkyl groups attached to the sulfur ([@bib2165]), and (3) β-elimination of alkyl/allyl thiols/persulfides from various alkyl/allyl cysteine *S*-conjugates present in garlic extracts ([@bib0445], [@bib1765]). Except for kynureninase, the remaining mammalian cysteine *S*-conjugate β-lyases listed in [Table 1](#t0010){ref-type="table"} are aminotransferases.

Most PLP-catalyzed reactions involving amino acids proceed through a quinonoid intermediate formed between substrate and active site PLP ([@bib0610], [@bib1525]). In the normal physiological reaction catalyzed by kynureninase, a quinonoid intermediate is converted to an enamine intermediate with resonance stabilized partial carbanion character at the terminal carbon (Eq. [29](#fo0150){ref-type="disp-formula"}) (where R = remainder of the quinonoid intermediate) ([@bib2060]). However, when DCVC binds to the active site, a β-elimination is catalyzed as a result of the strongly electron-withdrawing moiety attached at the sulfur. This results in the formation of an enamine with resonance stabilized partial carbocation character (Eq. [30](#fo0155){ref-type="disp-formula"}) (where R^+^ is the protonated pyridine form of the intermediate and R is a quinonoid intermediate). In the former case, alanine $\left\lbrack {{CH}_{3}CH\left( {{NH}_{3}}^{+} \right){{CO}_{2}}^{-}} \right\rbrack$ is released from the active site. In the latter case, aminoacrylate $\left\lbrack {{CH}_{2} = C\left( {{NH}_{3}}^{+} \right){{CO}_{2}}^{-}} \right\rbrack$ is released, which, as noted earlier, is nonenzymatically converted to pyruvate and ammonium ion.$$$$ $$$$

When transamination competes with the β-lyase reaction, an α-keto acid substrate such as α-keto-γ-methiolbutyrate (KMB) or phenylpyruvate (or PLP) must be present in the reaction mixture to maintain the β-elimination reaction. A half-transamination reaction will convert the PLP coenzyme to its pyridoxamine 5′-phosphate (PMP) form, which cannot catalyze a β-lyase reaction. The α-keto acid substrate forms a Schiff base with PMP that is converted to the corresponding amino acid and PLP. The PLP form of the enzyme can then catalyze another round of the β-lyase reaction ([@bib0425], [@bib2080]).

β-Elimination reactions catalyzed by aminotransferases have been known for at least 45 years. For example, pig heart cytAspAT catalyzes β-elimination reactions with β-chloroalanine, serine *O*-sulfate, and serine *O*-phosphate ([@bib1095], [@bib1590], [@bib2210]). The ratio of transamination to β-elimination depends in part on the electron-withdrawing properties (nucleofugacity) of the group attached at the β-position of the amino acid substrate. With β-chloroalanine and serine *O*-sulfate, only β-elimination can be detected in the presence of cytAspAT ([@bib1590], [@bib2210]). As noted earlier, several aminotransferases have been shown to catalyze a β-elimination reaction with TFEC ([Table 1](#t0010){ref-type="table"}). In most cases, transamination was shown to compete with β-elimination. Presumably, ---SCF~2~CF~2~H is a less effective nucleofuge than is ---Cl. However, the β-elimination to transamination ratio also depends on the enzyme. For example, for mitAspAT with TFEC as substrate, the ratio is \> 100 ([@bib0475]) but ∼ 2:1 for rat kidney GTK ([@bib0415]). Human BCAT~m~ can catalyze a β-lyase reaction with TFEC, but transamination cannot be detected ([@bib0485]).

In many cases, β-elimination catalyzed by aminotransferases leads to eventual syncatalytic inactivation. The inactivation of cytAspAT by β-chloro-[l]{.smallcaps}-alanine, however, can be decreased by inclusion in the reaction mixture of a Michael acceptor such as thiosulfate ([@bib0325]) or β-mercaptoethanol ([@bib0030]). The products obtained are [l]{.smallcaps}-cysteine *S*-sulfonate and 3-(2-hydroxyethyl)-[l]{.smallcaps}-cysteine, respectively. The inactivating species is evidently aminoacrylate. The aminoacrylate may be free in solution as suggested by [@bib0325] or covalently bound to PLP coenzyme ([@bib0030]). The latter is suggested by retention of configuration at the α-carbon of product 3-(2-hydroxyethyl)-[l]{.smallcaps}-cysteine when aminoacrylate is trapped with β-mercaptoethanol ([@bib0030]).

It was originally suggested that inactivation of cytAspAT by β-chloro-[l]{.smallcaps}-alanine is due to modification of a lysine residue by aminoacrylate ([@bib1590]). However, [@bib2210] presented evidence that the inactivation in the presence of serine *O*-sulfate is due to formation of the pyruvate--PLP aldol product. More recently, we showed that rat liver mitAspAT is syntactically inactivated by β-chloroalanine and TFEC on average after ∼ 3850 and ∼ 2700 turnovers per enzyme monomer, respectively ([@bib0475]). This difference was ascribed to the production of one reactive species (aminoacrylate or aminoacrylate bound as Schiff base) in the case of β-chloroalanine but two reactive species in the case of TFEC (aminoacrylate and ---SCF~2~CF~2~H). The eliminated sulfur-containing fragment is chemically very reactive (previous section). Earlier work had shown that the ε-amino groups of lysine residues are susceptible to thioacylation ([@bib0715], [@bib0885], [@bib0900], [@bib0905]).

As noted in [Table 1](#t0010){ref-type="table"}, TFEC is both a β-lyase and aminotransferase substrate of mitAspAT; the enzyme is also syncatalytically inactivated by TFEC ([@bib0500]). Inactivation is accompanied by several protein modifications. For example, eliminated fragments (structures **3** and **4**, [Fig. 5](#f0030){ref-type="fig"}) were found to covalently add to the ε-amine of susceptible lysine residues (H~2~NR), generating F~2~CCF~2~NHR and F~2~CC(S)NHR, respectively. Interestingly, the initial product of the elimination reaction (aminoacrylate or aminoacrylate in Schiff base linkage to PLP cofactor) was also found to covalently add to a susceptible protein residue. In this case, the addition is to a cysteine residue giving rise to a lanthionine residue ([@bib0500]).

Curiously, both human BCAT~m~ and BCAT~c~ can catalyze β-elimination with TFEC, but both enzymes are rapidly inactivated. Inactivation occurs on average ∼ 170--280 and 40--50 turnovers per subunit for BCAT~m~ and BCAT~c~, respectively ([@bib0485]). On the other hand, both rat kidney GTK and mouse GTL are resistant to inactivation by β-lyase substrates. Human GTK has an unusual "crown" of aromatic amino acid residues in the substrate binding pocket, which may account for the interaction with amino acids containing a neutral side group, including some cysteine *S*-conjugates ([@bib1860]). This arrangement may prevent access of reactive fragments to susceptible groups within the vicinity of the active site. Evidently, the relative ease of syncatalytic inactivation by β-lyase substrates varies greatly among the aminotransferases and probably depends on ease of access of reactive fragments to susceptible residues in the active site or vicinity of the active site.

The earlier discussion attests to the wide scope of *nonphysiological* β-elimination reactions that can give rise to highly reactive aminoacrylate. However, aminoacrylate is also the *physiological* end product of several PLP-catalyzed reactions. Insofar as aminoacrylate takes seconds to many minutes to be nonenzymatically converted to pyruvate and ammonia, the possibility exists that proteins and other macromolecules in the vicinity of the aminoacrylate-generating enzymes will be severely "damaged." It is of considerable interest, therefore, that nature has evolved enzymes (RidA proteins) that are widely distributed and that considerably accelerate the rate of conversion of aminoacrylate to pyruvate and ammonia, thereby lessening the impact of enzyme-generated aminoacrylate ([@bib0670], [@bib1660], [@bib1665]).

10.17.7. Major Cysteine *S*-Conjugate β-Lyases of Mammalian Tissues {#s0205}
===================================================================

As noted earlier, the first two mammalian cysteine *S*-conjugate β-lyases to be positively identified were kynureninase ([@bib2060]) and GTK ([@bib2080]). Because GTK is (1) particularly prominent in vitro as a β-lyase with toxic cysteine *S*-conjugates such as TFEC ([Table 1](#t0010){ref-type="table"}), (2) the enzyme is present in rat and human kidney proximal tubules (e.g., [@bib1110], [@bib0465], [@bib1160]), and (3) the proximal tubules are especially prone to damage from toxic halogenated cysteine *S*-conjugates; it was quickly assumed that GTK is synonomous with cysteine *S*-conjugate β-lyase. Indeed, GTK is given this name as a synonym in the human genome directory. The gene for the human enzyme cysteine conjugate beta-lyase 1 (*CCBL1*) is located on chromosome 9 ([@bib1755]). Cysteine conjugate beta-lyase 2 (*CCBL2*) is also noted to be present in the human genome. We have recently shown that this gene codes for GTL a protein closely related to GTK ([@bib1770]).

Naming GTK and GTL as cysteine *S*-conjugate β-lyases in the human genome is unfortunate because, as shown in [Table 1](#t0010){ref-type="table"}, other PLP-dependent enzymes catalyze cysteine S-conjugate β-lyase reactions and may also contribute to the formation of reactive fragments from nephrotoxic cysteine *S*-conjugates. Moreover, the cysteine *S*-conjugate β-lyase reactions are often not normally physiologically relevant. In the following sections, we focus on GTK and mitAspAT as major cysteine *S*-conjugate β-lyases in mammals.

10.17.7.1. GTK/Kynurenine Aminotransferase I {#s0210}
--------------------------------------------

The ability of glutamine to participate in enzyme-catalyzed transamination was first discovered by [@bib1515]. Subsequently, [@bib0435], [@bib0440] discovered that rat tissues contain at least two glutamine transaminases, a kidney type named glutamine transaminase K (GTK, highest specific activity in the kidney but well represented in other tissues), and a liver type named glutamine transaminase L (GTL, predominantly in the liver, with lower activity in other tissues). Very little work has been carried out on GTL. On the other hand, GTK has been extensively studied.

As summarized by [@bib0430], GTK in vitro exhibits a broad specificity toward [l]{.smallcaps}-amino acids and α-keto acids. In general, the enzyme has a preference for [l]{.smallcaps}-glutamine, [l]{.smallcaps}-methionine (and many other sulfur-containing amino acids), [l]{.smallcaps}-phenylalanine (and some other aromatic amino acids), and the corresponding α-keto acids. As noted earlier, cysteine *S*-conjugates are also substrates of rat kidney GTK. Interestingly, [l]{.smallcaps}-selenocysteine *Se*-conjugates are more active aminotransferase and β-lyase substrates of rat kidney GTK than are the corresponding cysteine *S*-conjugates, in most cases by an order of magnitude or more ([@bib0415]). As a consequence, GTK has been suggested to be a possible target for selenium-containing chemopreventive drugs ([@bib0415]). [l]{.smallcaps}-Glutamine is the major amino acid substrate in vivo. The product of glutamine transamination (i.e., α-ketoglutaramate, αKGM) is rapidly removed by cyclization to a lactam and/or conversion to α-ketoglutarate in a reaction catalyzed by ω-amidase. Transamination is therefore "pulled" in the direction of glutamine utilization. Major roles of GTK are to close the methionine salvage pathway by transamination of KMB, to salvage the α-keto acid analogs of essential amino acids, and possibly to generate cyclic sulfur-containing imines (reviewed by [@bib0430], [@bib1770], [@bib0505]). In addition, the glutamine transaminases coupled to ω-amidase may provide anaplerotic α-ketoglutarate as an energy source in rapidly dividing cells ([@bib0505]).

[@bib1750] reported the amino acid sequence deduced from the cDNA of an enzyme from rat kidney to which they assigned the name cysteine *S*-conjugate β-lyase. The authors showed that the monomer has a *M* ~r~ of 47 × 10^3^ and is composed of 423 amino acid residues. A conserved PLP binding site is present. Shortly thereafter, [@bib1600] deduced the amino acid sequence for rat kidney KAT I from the cDNA and expressed the enzyme in COS-1 cells. The expressed enzyme had both KAT and GTK activities; the two reported sequences are almost identical. The only difference is Ala for Arg at residue 107 and Val for Ile at residue 177 in the sequence deduced by [@bib1600] versus that deduced by [@bib1750]. [@bib1600] assumed that rat kidney KAT (actually KAT I) is identical to cysteine *S*-conjugate β-lyase and to GTK and that the differences between the sequences obtained by the two groups are due to variability in the strain of rats used.

GTK occurs in the cytosolic and mitochondrial fractions of rat tissues ([@bib0440]). Interestingly, the mitochondrial form of GTK/KAT I is identical to the cytosolic form except that the former contains an additional stretch of 32 amino acids at the N-terminus ([@bib1440]). To what extent the 32 amino acid leader sequence is cleaved after entry into the mitochondria is not clear. Apparently, the presence of cytosolic and mitochondrial forms is due to the presence of two mRNAs derived from the same gene coding for proteins, respectively, with and without mitochondria-targeting leader sequences ([@bib1440], [@bib1605]).

[@bib1605] cloned four cDNAs from a kidney cDNA library containing several different 5′-UTRs. One of the transcripts (+ 14KAT1 cDNA) contains an alternative translation initiation site. The authors showed that several KAT I mRNAs are expressed in a ubiquitous manner, whereas + 14KAT1 mRNA is present only in the kidney. The KAT I mRNAs exhibit different in vitro translational efficiencies, which correlate with the levels of enzyme activity in transfected COS-1 cells. The findings are in accord with the predicted accessibility of the ribosomal binding sites of the different mRNAs ([@bib1605]).

Human GTK was purified from the kidney tissue ([@bib1320]). Subsequently, human GTK was cloned and sequenced ([@bib0775], [@bib1755]). The deduced amino acid sequence of the human enzyme exhibits an 82% overall similarity to the deduced sequence of the rat enzyme with a 90% similarity around the PLP binding site. Recombinant human GTK (rhGTK) is a homodimer (subunit *M* ~r~ ∼ 47,900) containing one PLP per monomer ([@bib0825], [@bib1860]). Crystallized rhGTK/KAT I has the prototypical fold of an aminotransferase of subgroup I ([@bib1860]). As is typical of aminotransferases, the active site of rhGTK is open in the absence of substrate but changes to a more closed arrangement upon covalent attachment of the amino acid substrate to the PLP coenzyme. As noted earlier, the active site has a high degree of hydrophobicity that allows binding of amino acids and cysteine *S*-conjugates with large noncharged side groups.

To our knowledge, a possible mitochondrial form of human GTL has not been considered. The GTL thus far studied corresponds to a cytosolic form. However, we note from inspection of the human genome that alternative splicing could theoretically generate a 94 amino addition at the N-terminus that contains a mitochondrial-targeting sequence.

10.17.7.2. Mitochondrial Aspartate Aminotransferase {#s0215}
---------------------------------------------------

AspAT catalyzes the reversible transamination of glutamate and oxaloacetate to α-ketoglutarate and aspartate. Almost all mammalian tissues/cells investigated, with the notable exception of red blood cells, contain high levels of cytosolic and mitochondrial isozymes of AspAT. This ubiquity attests to the importance of these enzymes in amino acid metabolism. The two enzymes are also crucial components of the malate--aspartate shuttle for the transport of reducing equivalents (in lieu of NADH) between cytosol and mitochondrion ([@bib0720]). Oxaloacetate and α-ketoglutarate link amino acid metabolism to the tricarboxylic acid (TCA) cycle. Coupling of an α-ketoglutarate-/glutamate-linked aminotransferase to AspAT and the glutamate dehydrogenase reaction permits the flow of nitrogen from amino acid, to glutamate, to ammonium ion. When this occurs in the periportal cells of the liver, this flow directs excess amino acid nitrogen toward ammonium ion for urea synthesis. For a review of the metabolic importance of AspAT, see [@bib0420].

The sequences of many mitAspAT and cytAspAT enzymes are known, including those of human, pig, rat, and chicken. Several AspAT enzymes have been crystallized including chicken mitochondrial and cytosolic forms, the pig cytosolic form, and several bacterial forms ([@bib1510], [@bib1935]). These enzymes belong to the fold type I family, subclass I. It has long been known that the two isozymes of AspAT can utilize amino acids other than glutamate and aspartate as amino acid substrates. For example, they exhibit some activity with the aromatic amino acids ([@bib1530], [@bib1980]). Rat liver mitAspAT was also shown to readily catalyze transamination of cysteine ([@bib1980], [@bib2200]). Thus, it occurred to us that this enzyme might be able to utilize cysteine *S*-conjugates as substrates, and this turned out to be the case with rat liver mitAspAT ([@bib0475]; [Table 1](#t0010){ref-type="table"}). To the best of our knowledge, the ability of human mitAspAT to catalyze cysteine *S*-conjugate β-lyase reactions has not been investigated. However, given the similarity of members of the AspAT family, it seems a reasonable assumption that human mitAspAT will catalyze such a reaction.

10.17.8. Role of the Mercapturate Pathway and Cysteine *S*-Conjugate β-Lyases in the Bioactivation of Toxic Halogenated Alkenes {#s0220}
===============================================================================================================================

Acivicin, a selective inhibitor of GGT, protects renal tubule cells against DCVC-induced toxicity ([@bib0655], [@bib1300]). On the other hand, it has been reported that acivicin does not protect rats against the nephrotoxicity of hexachloro-1,3-butadiene ([@bib0560]). However, others have shown that *S*-(1,2,3,4,4-pentachloro-1,3-butadienyl)-[l]{.smallcaps}-cysteine (PCBC; the cysteine *S*-conjugate of hexachloro-1,3-butadiene) is cytotoxic to LLC-PK~1~ cells ([@bib0225]). AOA (a general inhibitor of PLP enzymes including aminotransferases) protects against DCVC-induced toxicity (e.g., [@bib0190], [@bib0225], [@bib0350], [@bib0355], [@bib1310]) and PCBC-induced toxicity ([@bib0225]) in LLC-PK~1~ cells. AOA partially protects against DCVC-induced toxicity in isolated rat kidney proximal tubules ([@bib1300]), but apparently not in isolated human renal proximal tubule cells ([@bib0530]). α-Keto acids stimulate the toxicity of DCVC toward rat renal cells ([@bib0660]), suggesting involvement of aminotransferase(s) in the bioactivation process. AOA protects isolated rat proximal tubule cells against TFEC and the cysteine *S*-conjugates of chlorotrifluoroethylene, 1,1-dichloro-2,2-difluoroethylene, and 1,1-dibromo-2,2-difluoroethylene ([@bib0240]). α-Methyl DCVC, which cannot be metabolized by a β-lyase reaction, is not toxic ([@bib0110]). Taken together, despite an occasional study to the contrary, the literature strongly supports important roles for GGT and cysteine *S*-conjugate β-lyases in promoting the nephrotoxicity of halogenated alkenes. However, it appears that human renal tissue is less susceptible than that of rat to damage from haloalkene cysteine *S*-conjugates, presumably as a result of lower specific activities of cysteine *S*-conjugate β-lyases in human renal tissue ([@bib1060], [@bib1320]) and allometric scaling ([@bib0090]).

Although the evidence is compelling that cysteine *S*-conjugate β-lyase reactions contribute to the nephrotoxicity of DCVC and other cysteine *S*-conjugates derived from halogenated alkenes, as noted earlier, the sulfoxides of the cysteine *S*-conjugate and mercapturates may be even more toxic than the cysteine *S*-conjugate ([@bib1330], [@bib1340], [@bib2355]). It has been suggested that the nephrotoxicity of DCVC sulfoxide is related in part to oxidative stress, possibly as a result of depleted mitochondrial GSH stores ([@bib1330], [@bib1340]). The β-lyase pathway may result in greater bioactivation of DCVC than does the oxidation pathway in rat proximal tubules, whereas the converse may be true for human proximal tubules ([@bib0530]).

1,3-Dichloropropene (a soil fumigant) increases the incidence of hepatocellular adenomas in male rats ([@bib1190]). The cysteine *S*-conjugate and corresponding mercapturate of both the *cis*- and the *trans*-isomers of 1,3-dichloropropene are cytotoxic to renal proximal tubules and to LLC-PK~1~ cells ([@bib0100], [@bib1730]). The 1,3-dichloropropene-induced cytotoxicity is inhibited by methimazole but not by AOA, indicating a role for FMO, but not for cysteine *S*-conjugate β-lyases. It was suggested that the cysteine *S*-conjugate sulfoxide (*S*-(3-chloroallylsulfinyl)-[l]{.smallcaps}-cysteine) undergoes a \[2,3\]-sigmatropic rearrangement to the sulfinate ester 2-amino-3-(1-chloroallyloxythio)propanoic acid, which may decompose to toxic acrolein and cysteine sulfinyl chloride ([@bib0100], [@bib1730]).

Thus, although much of the focus of this section is on bioactivation of haloalkene cysteine *S*-conjugates via cysteine *S*-conjugate β-lyases, it is important to note that other bioactivation pathways may exist. Moreover, species and sex differences in the mechanisms by which certain haloalkene cysteine *S*-conjugates are bioactivated must also be considered when evaluating the nephrotoxicity of halogenated cysteine *S*-conjugates (e.g., [@bib0210], [@bib1335], [@bib1345]).

10.17.9. Mechanisms Contributing to the Nephrotoxicity of Haloalkene Cysteine *S*-Conjugates: Toxicant Channeling {#s0225}
=================================================================================================================

Haloalkene cysteine *S*-conjugates are especially toxic to renal mitochondria (e.g., [@bib0110], [@bib0360], [@bib0800], [@bib1300]). Therefore, it follows that mitochondrial cysteine *S*-conjugate β-lyases may be particularly important in bioactivating toxic cysteine *S*-conjugates. Toxicity of DCVC to kidney cells has been associated with (1) covalent modification of macromolecules, (2) depletion of nonprotein thiols (presumably mostly GSH), (3) lipid peroxidation ([@bib0190], [@bib0350], [@bib0795]), and (4) carbonylation of susceptible proteins ([@bib0680]). These effects may be attributable to formation of metabolites derived from a β-lyase reaction since, as mentioned earlier, AOA can protect against DCVC toxicity in renal tissues and in renal cells in culture. Mechanisms by which metabolites of DCVC and other nephrotoxic haloalkene cysteine *S*-conjugates alter thiol status may involve direct inhibition of glutathione reductase ([@bib1405]) and generation of oxidative stress that leads indirectly to oxidation of thiol compounds ([@bib0350]). Oxidation of DCVC to DCVC sulfoxide followed by formation of a glutathione *S*-conjugate resulting from the reaction of DCVC sulfoxide with GSH may also lead to oxidative stress ([@bib1330], [@bib1900]). Other studies lead us to suggest an additional possibility, namely, that oxidative stress may result in part from Michael addition of thiols to aminoacrylate generated in the β-lyase reaction. In experiments in which LLC-PK~1~ cells were exposed to DCVC, the loss of nonprotein thiols was about 40--60% ([@bib0350]). Interestingly, the authors suggested that depletion of nonprotein thiols to this extent was insufficient to kill the cells. As cited earlier, BTC is relatively nontoxic, despite the fact that it is metabolized in vivo via cysteine *S*-conjugate β-lyases ([@bib0645]). We are unaware of any studies on GSH status in renal cells/tissue resulting from exposure to BTC. Evidently, even if GSH is depleted in renal cells exposed to BTC, this insult may not be sufficient to induce overt toxicity. The implication of the work by [@bib0350] is that in order for a cysteine *S*-conjugate to exhibit toxicity, it must generate reactive sulfur-containing fragments that covalently add to macromolecules. The toxicity may be enhanced, perhaps synergistically, by oxidative stress and by Michael adduction between aminoacrylate and susceptible nucleophiles such as GS^−^ and protein sulfhydryls and/or by modification of coenzyme in susceptible PLP enzymes.

Cysteine *S*-conjugate β-lyases are ubiquitous in the body. For example, as mentioned earlier, mitAspAT is present in every cell that contains mitochondria. How then can one explain the unusual susceptibility of the kidney to halogenated cysteine *S*-conjugates? Many factors are presumably involved ([@bib0240]), including relative distribution of *N*-acetyltransferase and aminoacylases, cellular and mitochondrial uptake mechanisms, susceptibility to inactivation of cysteine *S*-conjugate β-lyases and nearby enzymes/macromolecules, relative *K* ~m~ values, competition from natural amino acid substrates, absolute level of the enzyme, the presence of the enzyme in mitochondria, and the presence of α-keto substrate to keep the enzyme enzymatically active (if the lyase in question is an aminotransferase). A major contributing factor is likely to be the very large surface area of the renal proximal tubules coupled to the extraordinary high renal vascular perfusion. In humans, the kidneys represent 0.4% of the body weight but receive 25% of the cardiac output ([@bib1760]); the cortex receives 95% of the renal blood flow. Despite these factors, haloalkene cysteine *S*-conjugate-induced toxicity is not necessarily confined to renal tubules. As we have noted earlier, toxicity may also occur in the liver and occasionally in neural tissue, presumably as a consequence of the widespread tissue occurrence of cysteine *S*-conjugate β-lyases.

The question may be asked "are there any clues as to which enzymes are responsible for the bioactivation of toxic halogenated cysteine *S*-conjugates?" [Table 1](#t0010){ref-type="table"} suggests that GTK is an obvious choice. As noted earlier, GTK activity is present in cytosolic and mitochondrial fractions of the rat kidney. However, most of the activity is in the cytosolic fraction ([@bib0440]), and most of the β-lyase activity toward DCVC in rat kidney mitochondria could not be assigned to GTK ([@bib0015]). Thus, although GTK probably contributes to the bioactivation of toxic halogenated cysteine *S*-conjugates in the rat kidney, other cysteine *S*-conjugate β-lyases presumably play an important role in the mitochondrial damage.

Although the in vitro specific activity of mitAspAT as a β-lyase toward DCVC and TFEC is somewhat lower than that of GTK ([Table 1](#t0010){ref-type="table"}), the very high level of this enzyme in kidney mitochondria ([@bib1740]) suggests that this enzyme might play a prominent role in bioactivation of nephrotoxic halogenated cysteine *S*-conjugates ([@bib0480]). The importance of mitAspAT as a cysteine *S*-conjugate β-lyase in the bioactivation of TFEC is underscored by the work of [@bib0260]. These authors showed that six kidney mitochondrial proteins are thioacylated after rats are acutely administered a high dose of TFEC. No thioacylation of cytosolic kidney proteins was detected (negating an important role for cytosolic GTK in this process). The six proteins were identified as HSP60, mitHSP70, mitAspAT, aconitase, the E~2~k (dihydrolipoamide succinyl transferase) enzyme component of the KGDHC, the E~3~ (dihydrolipoamide dehydrogenase) enzyme component of KGDHC, and the E~3~ enzyme component of the branched-chain keto acid dehydrogenase complex (BCKADHC) ([@bib0260], [@bib0265], [@bib0270], [@bib1080]). [@bib1405] had previously reported that metabolites of haloalkene cysteine *S*-conjugates (DCVC, TFEC, and PCBC) inhibited dihydrolipoyl dehydrogenase (E~3~). Our findings that mitAspAT catalyzes a cysteine *S*-conjugate β-lyase reaction with TFEC in vitro and is syncatalytically inactivated in the process ([@bib0475]) are consistent with the in vivo finding that this enzyme in the kidney is thioacylated after administration of TFEC to rats ([@bib0500]). We also showed that a high-*M* ~r~ cysteine *S*-conjugate β-lyase present in the kidney copurifies with HSP70 ([@bib0470]). As cited earlier, the high-*M* ~r~ cysteine *S*-conjugate β-lyase in rat kidney mitochondria contains mitAspAT. This finding provides a mechanism for the prior finding of thioacylation of kidney mitHSP70 in rats administered TFEC. Conceivably, mitochondrial HSP60 may also associate with a PLP-containing enzyme that catalyzes a β-lyase reaction with TFEC.

Although the E~2~k and E~3~ enzyme components of KGDHC (and the E~3~ enzyme component of BCKADHC) are thioacylated in kidney mitochondria of rats administered TFEC, the E~2~p (dihydrolipoamide acetyl transferase) and E~3~ enzyme components of PDHC are not ([@bib0270], [@bib1080]). Moreover, the specific activity of KGDHC, but not that of PDHC, is diminished in the kidneys of TFEC-treated rats ([@bib0270]). We have found that KGDHC, but not PDHC, is directly inhibited in PC12 cells exposed to 1 mM TFEC ([@bib1735]). These findings are remarkable because E~3~ is a common component of KGDHC, PDHC, and BCKADHC (and the glycine cleavage system). In the presence of TFEC and purified GTK (a source of thioacylating moieties), purified PDHC is more resistant to in vitro inactivation than is purified KGDHC ([@bib1735]). Moreover, there is some evidence that E~3~ enzyme components are bound to the complex via E~2~ enzyme components in PDHC, whereas E~3~ enzyme components are bound to the complex via E~1~ enzyme components in KGDHC ([@bib1500]). Thus, part of the resistance of PDHC to thioacylation/inactivation in kidney mitochondria of TFEC-treated rats may be due to differences in the arrangement of its constituent enzymes within the enzyme complex. In addition, PDHC is not known to be associated with any aminotransferases/β-lyases, whereas KGDHC is closely associated with mitAspAT. Thus, the susceptibility of KGDHC to thioacylation by a fragment derived from TFEC may be due to the proximity of mitAspAT or actual colocalization with subunit enzymes ([@bib1080], [@bib1735]).

Several TCA cycle enzymes and TCA-associated enzymes have been proposed to be arranged in supramolecular complexes (metabolons) that facilitate channeling of substrate from one enzyme to another. For example, mitAspAT has been proposed to be part of a metabolon affiliated or localized with KGDHC (see references cited in [@bib0480]). Based on our findings ([@bib0475], [@bib0485]) and those of Bruschi and coworkers ([@bib0270], [@bib1080]), we have proposed that not only are metabolites channeled through supramolecular complexes in the TCA cycle but toxicants are also channeled ([@bib0480]; [Fig. 6](#f0035){ref-type="fig"} ). This concept explains not only the susceptibility of KGDHC to TFEC-induced inactivation in rat kidney and cells in culture but also the susceptibility of aconitase and BCKADHC to thioacylation/inactivation. Aconitase has been proposed to be part of a metabolon that includes KGDHC and mitAspAT ([@bib1080], [@bib1720]). Evidence also suggests that substrate channeling occurs between a metabolic unit (termed branched-chain amino acid metabolon) consisting of human BCAT~m~ and BCKADHC and that the channeling is influenced by the redox state in mitochondria ([@bib1045], [@bib1050]). This finding would explain the susceptibility of kidney BCKADHC to TFEC-induced inactivation. Although most of the studies in support of substrate channeling of TCA intermediates have utilized indirect methods, more recent physicochemical methods have provided more direct evidence for TCA substrate channeling (e.g., [@bib2420]). The studies of [@bib2420] are consistent with the possibility of toxicant channeling.Fig. 6Model of toxicant channeling of β-lyase-derived TFEC products in mitochondria. TFEC is transported into the mitochondrion where it is converted by cysteine *S*-conjugate β-lyases to aminoacrylate (AMAC) and a reactive sulfur-containing fragment (RSH). AMAC not only is nonenzymatically converted to pyruvate and ammonium ion but also may react with PLP cofactor or susceptible protein residues. The three mitochondrial α-keto acid dehydrogenase complexes (BCKADHC, KGDHC, and PDHC) are represented as multimeric units. Mitochondrial cysteine *S*-conjugate β-lyases include the homodimeric BCAT~m~ and the homodimeric mitAspAT. The close juxtapositioning of BCAT~m~ and mitAspAT to enzymes of energy metabolism results in channeling of toxicants to BCKADHC and to KGDHC/aconitase (Aco 2), respectively, resulting in their inactivation. PDHC is not known to be associated with any aminotransferase/cysteine *S*-conjugate β-lyase and is not directly inactivated. The curved arrows represent syncatalytic inactivation of BCAT~m~ and mitAspAT by AMAC and RSH. IM, inner mitochondrial membrane; OM, outer mitochondrial membrane; and M, matrix.Modified from Cooper, A.J.L., Pinto, J.T., 2008. In Elfarra, A.A. (ed.), Biotechnology: Pharmaceutical Aspects. Advances in Bioactivation Research. Springer, New York, NY.

Toxicant channeling may provide an explanation for the finding that the S~3~ segments of the proximal tubules are especially vulnerable to cysteine *S*-conjugates derived from halogenated alkenes. The S~3~ region of the proximal tubule has a high metabolic rate ([@bib1235]), and KGDHC is an important control step in the TCA cycle ([@bib0765]). Thus, inactivation of KGDHC by chemically reactive compounds generated by the action of cysteine *S*-conjugate β-lyase(s) is expected to be especially serious in the S~3~ segments. Inhibition of KGDHC and aconitase may lead to metabolic stress, which in turn may lead to oxidative stress.

10.17.10. Homocysteine *S*-Conjugates {#s0230}
=====================================

A few toxicological studies have been carried out with the homocysteine *S*-conjugate analogs of DCVC and BTC ([@bib0110], [@bib1315], [@bib1320], [@bib1325]). While these compounds are unlikely to be formed from electrophilic xenobiotics in vivo to any large extent, they are instructive model compounds. *S*-(1,2-Dichlorovinyl)-[l]{.smallcaps}-homocysteine (DCVHC) is even more toxic than is DCVC, and the toxicity is potentiated by α-keto acids. Several amino acids that contain a good leaving group in the γ-position undergo a nonenzymatic β,γ-elimination reaction when converted to the corresponding α-keto acid by an aminotransferase or [l]{.smallcaps}-amino acid oxidase ([@bib0965] and references quoted therein). Activation of the β C---H bond in the α-keto acid (or α-imino acid) facilitates a β,γ-elimination reaction with the production of vinylglyoxylate (2-oxo-3-butenoic acid) (Eq. [31](#fo0160){ref-type="disp-formula"}). This compound is extremely unstable but can be trapped with a suitable mercaptan ([@bib0460], [@bib1325]).$$\left. {XCH}_{2}{CH}_{2}C\left( O \right){{CO}_{2}}^{-}\rightarrow XH + {CH}_{2} = CHC\left( O \right){{CO}_{2}}^{-} \right.$$

The increased toxicity of DCVHC relative to DCVC is presumably due to the fact that both compounds generate a toxic reactive sulfur-containing fragment following an elimination reaction. However, the other fragment generated in the β-lyase reaction on DCVC is aminoacrylate, which may be less toxic than vinylglyoxylate generated in the β,γ-elimination reaction on the keto analog of DCVHC ([@bib1325]).

Electrophilic estrogen quinones have been shown to react directly with homocysteine to form homocysteine *S*-conjugates ([@bib0725]). It was suggested that this reaction in vivo could lower the levels of toxic HCys and quench reactive estrogen quinones, resulting in cardiovascular protective effects ([@bib0725]).

10.17.11. Electrophilic Xenobiotics Metabolized through the Mercapturate Pathway {#s0235}
================================================================================

10.17.11.1. General Considerations {#s0240}
----------------------------------

Many xenobiotics have been tested for their ability to be detoxified by the mercapturate pathway. A detailed summary was published by [@bib0340]. No attempt is made here to update this list. Rather, a summary of the types of organic compounds listed by Chasseaud is provided as representative of electrophilic xenobiotics that generate mercapturates when administered to experimental animals (rabbits and rats have been most extensively tested): halogenated benzenes, halogenated nitrobenzenes, other arylnitro compounds, chloro-*S*-triazines (herbicides), phenoltetrabromophthaleins, aralkyl halides, alkyl and alicyclic halides, sulfates and nitro compounds, allyl compounds, alkyl methanesulfonates, organophosphorus compounds, polycyclic aromatic hydrocarbons (via arene oxides), various α,β-unsaturated compounds (esters, aldehydes, ketones, lactones, nitriles, nitro compounds, and sulfones), arylamines, arylhydroxylamines, carbamates, and related compounds. This list exemplifies the versatility and the importance of GSH and the mercapturate pathway for the detoxification of a large number of electrophilic xenobiotics. However, as documented earlier, the pathway may sometimes be a "double-edged sword." On the one hand, the mercapturate pathway is a defense mechanism to rid the body of potentially noxious xenobiotics. On the other hand, each of the various *S*-conjugates derived from halogenated alkenes within the mercapturate pathway is toxic as a result of bioactivation of the cysteine *S*-conjugate by cysteine *S*-conjugate β-lyases.

In the next section, we discuss electrophilic drugs that are metabolized by the mercapturate pathway or the mercapturate/cysteine *S*-conjugate β-lyase pathway.

10.17.11.2. Drugs Metabolized by the Mercapturate Pathway or by the Mercapturate/β-Lyase Pathway {#s0245}
------------------------------------------------------------------------------------------------

Examples of drug electrophiles (discussed by [@bib2000]) that are metabolized in part by pathways involving glutathione *S*-conjugate formation include the anticancer drug busulfan (see the succeeding text), the vasodilator nitroglycerin ([@bib1650]), and the immunosuppressive drug azathioprine ([@bib0570]). Some metabolites of morphine with electrophilic centers are powerful Michael acceptors of GSH ([@bib0515]).

The carbonic anhydrase inhibitor methazolamide is metabolized to glutathione *S*-conjugate and a cysteine *S*-conjugate. The latter is a substrate of cysteine *S*-conjugate β-lyase(s) in bovine kidney and liver homogenates ([@bib1175]). Cysteine *S*-conjugate β-lyases are also presumably present in eye tissues. Therefore, the β-elimination reaction may account for the binding of a metabolite of methazolamide to macromolecules and for the specific ocular toxicity ([@bib1175]).

Cisplatin is used to treat germ cell tumors, ovarian cancer, head and neck tumors, and as a radiation sensitizer for cervical cancer. Unfortunately, its effectiveness can be limited particularly during tumor recurrence by its toxicity to renal proximal tubule cells (reviewed in [@bib2465]). DNA damage is the primary mechanism by which cisplatin kills tumor and other dividing cells. However, the renal proximal tubule cells are well-differentiated, nondividing cells that are not killed by other DNA-damaging agents ([@bib0840]). Evidence has been presented that damage to kidney cells is due to conversion of cisplatin to its glutathione *S*-conjugate and subsequently to its cysteine *S*-conjugate. The cysteine *S*-conjugate is then bioactivated by cysteine *S*-conjugate β-lyase(s) to generate a fragment containing a Pt---SH moiety. This Pt---SH (or Pt---S^−^) fragment is proposed to react with macromolecules at thiophilic centers ([@bib2465]; [Fig. 7](#f0040){ref-type="fig"} ).Fig. 7Bioactivation of cisplatin through the mercapturate/cysteine *S*-conjugate β-lyase pathway. Cisplatin reacts with GSH in a reaction enhanced by GSTs (glutathione *S*-transferases). Protection against cisplatin toxicity by acivicin and AOA suggests the involvement of GGT and cysteine *S*-conjugate β-lyases, respectively, in the bioactivation of cisplatin. The lyase reaction is expected to release a fragment containing a reactive Pt--S bond.Reproduced from Zhang, L., Hanigan, M.H., 2003. Role of cysteine *S*-conjugate β-lyase in the metabolism of cisplatin. Journal of Pharmacology and Experimental Therapeutics 306, 988--994.

After mice were treated with cisplatin, proteins in kidney mitochondria were more platinated than proteins in the cytosolic fraction ([@bib2475]). Moreover, the platination was decreased in the mitochondrial fraction, but not in the cytosolic fraction, in mice pretreated with AOA. The specific activities of mitAspAT, aconitase, and especially KGDHC were decreased in LLC-PK~1~ cells treated with cisplatin ([@bib2475]). The specific activity of KGDHC was decreased even further in cisplatin-treated LLC-PK~1~ cells overexpressing mitAspAT. The data are consistent with the hypothesis that the cysteine *S*-conjugate of cisplatin is a β-lyase substrate of mitAspAT and that the released Pt---SH fragment reacts with proteins in kidney mitochondria especially KGDHC.

Another interesting example of a drug that is metabolized through the mercapturate pathway is busulfan ([@bib1465]). Busulfan is a bifunctional alkylating agent used for the treatment of hematologic and other malignancies prior to stem cell transplantation (e.g., [@bib1055]). The mercapturate pathway of busulfan metabolism was shown to occur in rats by the detection of the sulfonium mercapturate and *N*-acetyl-β-(*S*-tetrahydrothiophenium)-[l]{.smallcaps}-alanine in the urine ([@bib0895]). Busulfan is converted to a glutathione *S*-conjugate ([l]{.smallcaps}-γ-glutamyl-β-(*S*-tetrahydrothiophenium)-[l]{.smallcaps}-alanylglycine) by direct interaction with GSH ([@bib1835]) and enzymatic catalysis by GSTs, especially GSTA1-1 ([@bib0545], [@bib0760], [@bib1835], [@bib1840]). Oxidation products of tetrahydrothiophene (THT) make up the majority of identified busulfan metabolites in rodents and rabbits ([@bib1845]). 1,4-Diiodobutane and 1,4-dibromobutane are also converted to [l]{.smallcaps}-γ-glutamyl-β-(*S*-tetrahydrothiophenium)-[l]{.smallcaps}-alanylglycine and to the corresponding mercapturate in the rat ([@bib1460], [@bib1465], [@bib1695]).

The busulfan--glutathione adduct undergoes a nonenzymatic β-elimination reaction yielding THT at pH 8.0 ([@bib1845]). Presumably, therefore, THT can arise nonenzymatically from the glutathione *S*-conjugate in vivo. However, THT is also likely to arise via an enzymatic route ([@bib0495]). The detection of the mercapturate in rats shows that the cysteine *S*-conjugate must have been generated in vivo either by direct reaction of busulfan with cysteine or via the glutathione *S*-conjugate. The cysteine *S*-conjugate of busulfan (β-(*S*-tetrahydrothiophenium)-[l]{.smallcaps}-alanine, THT-A) is unusual in that the sulfur is in the oxidation state of a sulfonium rather than a thioether. Since sulfonium compounds are high-energy compounds, a β-elimination reaction yielding THT and aminoacrylate should be energetically favorable. Indeed, we have found that (1) homogenates of the rat liver, kidney, and brain; (2) μM PLP; and (3) highly purified rat liver cystathionine γ-lyase can catalyze a β-elimination reaction with THT-A ([@bib0495]). A scheme for the possible routes involved in busulfan metabolism is shown in [Fig. 8](#f0045){ref-type="fig"} .Fig. 8Proposed mechanism for the metabolic conversion of busulfan to THT. The strong electron-withdrawing properties of the ---OS(O~2~)CH~3~ group on busulfan (**I**) result in electron deficiency at each carbon adjacent to the two methanesulfonyl groups. This deficiency facilitates the nucleophilic attack of the sulfhydryl of GSH at one of these carbons, resulting in elimination of methanesulfonate (**II**) and subsequent generation of adduct **III**. This step occurs nonenzymatically but is accelerated by GSTs. The electron deficiency in the remaining carbon adjacent to the ---OS(O~2~)CH~3~ group in adduct **III** facilitates nonenzymatic intramolecular nucleophilic attack at this carbon by a pair of electrons on the sulfur of the thioether, generating the glutathione *S*-conjugate (**V**) and eliminating a second equivalent of methanesulfonate. The conjugate (**V**) possesses a cyclic sulfonium group. GGT (**a**) and dipeptidases (**b**) possess broad specificities. Thus, **V** is expected to be readily converted to the corresponding cysteine *S*-conjugate THT-A (**VI**). **VI** may also be formed by nonenzymatic nucleophilic attack of a cysteine sulfur on busulfan (**I**), which generates adduct **IV** and methanesulfonate, followed by intramolecular cyclization and elimination of a second equivalent of methanesulfonate. **VI** contains a strong electron-withdrawing group and is therefore expected to undergo a facile β-elimination reaction to yield THT (**VII**), ammonium ion (**VIII**), and pyruvate (**IX**). This reaction occurs nonenzymatically at pH 7.4 but is accelerated by PLP and by rat liver cystathionine γ-lyase (and by other as yet unrecognized enzymes in rat tissues). THT (**VII**) may also be generated directly and nonenzymatically from γ-E-THT-AG (**V**) by an elimination reaction that results in the formation of γ-glutamyldehydroalanylglycine (EdAG) (**X**). The conversion of busulfan (**I**) to the conjugate (**V**) is shown as occurring in two consecutive steps but may occur by a concerted mechanism. Note that the sulfur in THT is not derived from busulfan but rather from the sulfur of GSH.

It is not clear whether the β-elimination reactions with the busulfan *S*-conjugates on balance are detoxification or bioactivation events. Formation of THT is probably a detoxification event. However, the formation of aminoacrylate may be a bioactivation event if it leads to selected enzyme inactivation or removal of endogenous thiols. The formation of a GSH analog in which the cysteine of GSH is replaced by a dehydroalanine residue (γ-glutamyldehydroalanylglycine (EdAG); [Fig. 8](#f0045){ref-type="fig"}, structure X) may also be a bioactivation event. It is expected that Michael addition of sulfides across the double bond will occur. In this context, it has been shown that Michael addition of EdAG to GSH results in a GSSG analog in which the disulfide bond of GSSG is replaced by a stable, nonreducing ether bond ((2-amino-5-\[\[3-\[2-\[\[4-amino-5-hydroxy-5-oxopentanoyl\]amino\]-3-(carboxymethylamino)-3-oxopropyl\]sulfanyl-1-(carboxymethylamino)-1-oxopropan-2-yl\]amino\]-5-oxopentanoic acid); GSG) ([@bib2460]). Thus, formation of EdAG may be deleterious by lowering GSH levels and/or interfering with enzymes that normally utilize GSH/GSSG. It has recently been shown that a reactive cysteine residue in the actives site of glutaredoxin 1 (or glutaredoxin 2) (Grx 1/2) reacts with EdAG to form an irreversible thioether ([@bib1950]). The enzyme is inactivated in the process. The authors suggested that the adduction of Grxs by EdAG suggests the possible alteration of proteins that are normally regulated via Grx-dependent reversible glutathionylation or deglutathionylation. Dysregulation of Grx-dependent processes could contribute to cellular toxicity of busulfan.

10.17.12. Conclusions {#s0250}
=====================

Conversion of an electrophile to the corresponding glutathione *S*-conjugate and thence to the mercapturate followed by excretion represents a detoxification process. As noted earlier, a very large number of potentially toxic electrophilic xenobiotics are eliminated by this process. In addition, some natural metabolites (e.g., leukotrienes, prostaglandin (PG)A2, 15-deoxy-Δ^12,14^-PGJ~2~, and hydroxynonenal) may be eliminated as their corresponding mercapturates. However, formation of a glutathione *S*-conjugate may sometimes lead to bioactivation (toxification). For example, glutathione *S*-conjugates of some hydroquinones and dihaloethanes may be directly toxic. In other cases, the cysteine *S*-conjugate derived from the glutathione *S*-conjugate may be toxic. For example, the cysteine *S*-conjugate of dopamine can form potentially highly toxic benzothiazines. In other cases, the sulfur of the thioether linkages of the *S*-conjugates of the mercapturate pathway may be oxidized to sulfoxides that are more toxic than the corresponding thioethers. For example, DCVC sulfoxide may be more toxic than DCVC. The potential exists for the cysteine *S*-conjugate sulfoxide to undergo an elimination reaction to generate a reactive sulfenic acid. However, there is no evidence that this occurs in the case of DCVC sulfoxide. In this case, the toxicity of the sulfide may be associated with depletion of GSH.

If the cysteine *S*-conjugate formed in the mercapturate pathway contains a good electron-withdrawing group (nucleofuge), it may undergo a β-elimination reaction. This reaction is catalyzed by several PLP-containing cysteine *S*-conjugate β-lyases that are normally involved in amino acid metabolism. If the eliminated sulfur-containing fragment is not especially reactive, the parent cysteine *S*-conjugate may not be particularly toxic (although some limited toxicity may be associated with the elimination product aminoacrylate). The sulfur-containing fragment may be thiomethylated or *S*-glucuronidated and excreted. Alternatively, the fragment may be further oxidized to a sulfoxide or sulfone before excretion. On the other hand, if the eliminated sulfur-containing fragment is chemically reactive (e.g., by covalently reacting with macromolecules), the parent cysteine *S*-conjugate may be toxic, especially to the kidneys. Electrophiles that are bioactivated by this mechanism include halogenated alkenes and drugs such as methazolamide and cisplatin. Some PCBS and aminophenols may also be metabolized in part by pathways involving cysteine *S*-conjugate β-lyases. However, the contribution of the β-lyase reaction to the toxicity of these compounds is not clear. Mitochondrial enzymes of energy metabolism (KGDHC, aconitase) are especially vulnerable to reactive fragments generated from toxic halogenated, cysteine *S*-conjugates, by a process that has been termed toxicant channeling. Throughout life, humans are exposed to a large number of exogenously and endogenously produced electrophiles. It is, therefore, possible that cysteine *S*-conjugate β-lyases contribute to mitochondrial dysfunction of aging and disease.

The recent discovery that the cysteine *S*-conjugate of busulfan/dihalobutane, which is a sulfonium conjugate, can undergo enzyme-catalyzed β-elimination suggests that other drugs or xenobiotics may also undergo similar transformations involving sulfonium conjugates. 1-(Glutathione-*S*-yl)thiiranium and the corresponding cysteine *S*-conjugate (1-(2-amino-2-carboxyethyl)thiiranium) formed from dihalopropanes are highly toxic. By analogy with the cysteine *S*-conjugate β-lyase reaction with the cysteine *S*-conjugate THT-A, we predict that a β-lyase reaction on 1-(2-amino-2-carboxyethyl)thiiranium will lead to elimination of thiirane, which may possibly be a bioactivation event.

In view of (1) the large number of mammalian cysteine *S*-conjugate β-lyases identified to date, (2) their overlapping specificities, (3) their widespread occurrence in tissues, (4) their presence in different subcellular compartments (e.g., cytosol, mitochondria, and peroxisomes), and (5) the increasingly recognized wide scope of these reactions, the potential of these enzymes for generating toxic products in different subcellular compartments, not only in the kidneys but also in other tissues, is highly significant. In contrast, it is becoming apparent that some plants and microorganisms use the mercapturate pathway to generate useful sulfur-containing compounds. We suggest that metabolism of some natural products, certain drugs, and endogenously produced electrophiles via pathways that include the mercapturate pathway coupled to cysteine *S*-conjugate β-lyases may be more common than is generally appreciated.

See also {#s9000}
========

10.16. Glutathione Transferases.

Abbreviations {#no0010}
=============

AGAT II

:   Alanine-glyoxylate aminotransferase isoenzyme II

AlaAT

:   Alanine aminotransferase

ANIT

:   1-Naphthylisothiocyanate

AOA

:   Aminooxyacetate

APN

:   Aminopeptidase N

AspAT

:   Aspartate aminotransferase

BCAT~c~

:   Cytosolic branched-chain amino acid aminotransferase

BCAT~m~

:   Mitochondrial branched-chain amino acid aminotransferase

BCKADHC

:   Branched-chain keto acid dehydrogenase complex

BTC

:   *S*-(2-Benzothiazolyl)-[l]{.smallcaps}-cysteine

CCBL1

:   Cysteine conjugate β-lyase 1

CCBL2

:   Cysteine conjugate β-lyase 2

Cyt

:   Cytosolic

DCVC

:   *S*-(1,2-Dichlorovinyl)-[l]{.smallcaps}-cysteine

DCVHC

:   *S*-(1,2-Dichlorovinyl)-[l]{.smallcaps}-homocysteine

FMO

:   Flavin-dependent monooxygenase

GGT

:   γ-Glutamyltransferase

GSH

:   Glutathione (γ-glutamylcysteinylglycine)

GST

:   Glutathione *S*-transferase

GTK

:   Glutamine transaminase K

GTL

:   Glutamine transaminase L

KAT

:   Kynurenine aminotransferase

KGDHC

:   α-Ketoglutarate dehydrogenase complex

KMB

:   α-Keto-γ-methiolbutyrate

Mit

:   Mitochondrial

PCBC

:   *S*-(1,2,3,4,4-Pentachloro-1,3-butadienyl)-[l]{.smallcaps}-cysteine

PD

:   Parkinson disease

PDHC

:   Pyruvate dehydrogenase complex

PG

:   Prostaglandin

PLP

:   Pyridoxal 5′-phosphate

PMP

:   Pyridoxamine 5′-phosphate

rhGTK

:   Recombinant human GTK

TCA

:   Tricarboxylic acid

TCVC

:   *S*-(1,2,2-Trichlorovinyl)-[l]{.smallcaps}-cysteine

TFEC

:   *S*-(1,1,2,2-Tetrafluoroethyl)-[l]{.smallcaps}-cysteine

THT

:   Tetrahydrothiophene

THT-A

:   β-(*S*-Tetrahydrothiophenium)-[l]{.smallcaps}-alanine

UTR

:   Untranslated region
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[^1]: This table is an update of that of [@bib0450], [@bib0455] and [@bib0500]. See also [@bib1770] and [@bib0505]. A unit of enzyme activity (U) is defined as the amount of enzyme that catalyzes the formation of 1 μmol of pyruvate per min (usually at 37°C but temperature was not always specified). *ND*, not determined; *R*, rat; *P*, pig; *H*, human; and *m*, mouse

[^2]: Activity with DCVC and/or TFEC.

[^3]: Human liver contains a KAT with strong cysteine *S*-conjugate β-lyase activity. A cysteine *S*-conjugate β-lyase has been highly purified from human kidney. The lyase activity copurifies with GTK. The human GTK, unlike the rat enzyme, has activity with BTC. Some GTK activity is also found in rat kidney and liver mitochondria, but the role of mitochondrial GTK as a cysteine *S*-conjugate β-lyase is uncertain.

[^4]: Activity is also present in the cytosol.
